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 Abstract 
Food allergy represents an increasing concern to society. It is defined as an 
inappropriate immunological reaction to normally harmless food components and affects 
5-8% of children and 1-2% of adults. Since at the time of writing no cure for food allergy 
exists, food allergic consumers need to avoid all problematic foods and ingredients, 
which may have a negative impact on the quality of life and economic functioning of food 
allergic consumers and their families.  Food allergies may also result in substantial costs 
for society overall in terms of health care costs and absenteeism.  
Novel foods are continuously being developed and introduced onto the European 
market. The novelty of a food can be the result of: (1) genetic modification (GM) of the 
food itself, or its production using genetically modified organisms, (2) the application of 
novel processing techniques, or (3) the food in question having no prior history of 
consumption in general, or in a specific region or country. One potential benefit of novel 
foods is that of hypoallergenicity, although there is the potential risk that new proteins are 
introduced into the human food chain together with the novel foods. 
The aim of the research presented in this thesis is to investigate whether novel 
foods can be used as part of an allergy management strategy. The issues associated 
with novel foods and food allergy are identified and insight is gained in stakeholder and 
consumer attitudes towards the application of novel foods as allergy management 
strategy. In addition, the existing novel food legislation regarding novel foods is reviewed 
with respect to risks (and benefits) of novel foods associated with food allergy. 
The results show that that although hypoallergenic novel foods can have some 
positive contribution to food allergy management, their influence remains limited because 
many other factors other than the available foods cause the food allergy problems. 
Overall, this research contributes to a better understanding of the impact of food 
allergy on daily lives of food allergic consumers and shows that although hypoallergenic 
novel foods can facilitate allergen avoidance, their influence remains limited because 
many other factors, such as the recognition of their allergy by their social environment 
cause the food allergy problems. Nevertheless, considering that the food allergy 
management options are limited, the contribution that hypoallergenic novel foods, which 
can be replacement for allergenic foods may be valuable for consumers who are allergic 
to foods that are easy to recognise and avoid. 
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Chapter 1 
General introduction 
 
Allergies are a serious health problem. Many research activities have focussed on 
the medical treatment of allergic patients. The Allergy Consortium Wageningen aims to 
increase and communicate knowledge about allergens and allergy prevention with the 
focus on “Strategies for allergy management”. The research presented in this thesis 
about ‘Novel foods and food allergy’ is part of the Allergy Consortium’s research 
program, which also includes research on ‘Allergens in the green environment’, 
‘Allergens in the food production chain’, ‘The role of lifestyle factors in the development 
of food allergies’, and on ‘Celiac Disease’. 
 
1.1 Food allergy 
Food allergy is a complex disease, with genetic predisposition, environmental 
factors and exposure conditions all contributing to inter-individual differences in 
susceptibility. Figure 1 provides an overview of the classification of adverse reactions to 
food.  
 
Figure 1.1: Classification of adverse food reactions (Patriarca et al., 2009). 
 
Food allergy is defined as a hypersensitivity reaction that involves the immune 
system. Allergic reactions can be Immunoglobulin E (IgE) mediated, or non-IgE 
mediated. Examples of IgE mediated reactions are food and airway allergies. Examples 
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of non-IgE mediated reactions are celiac disease and contact dermatitis (Cox et al., 
2007; Patriarca et al., 2009). Hypersensitivity reactions that do not involve the immune 
system are not considered as food allergies. Instead, these are called non- allergic food 
hypersensitivity, sometimes also referred to as food intolerance, which can be caused by 
pharmacologic, or enzymatic triggers (Patriarca et al., 2009).  
True food allergy affects 5-8% of children and 1-2% of adults, although about 
20% of people report an adverse reaction to food (Mills et al., 2007). The majority 
(approximately 90%) of food allergic reactions are caused by eight foods: milk, egg, 
peanuts, tree nuts, fish, soya, wheat and shellfish (Cox, 2008). Although controversy 
exists as to whether the prevalence of food allergy is increasing, it non-the-less remains 
an important health issue (Dearman and Kimber, 2009). Food allergy can also be the 
result of cross-reactivity, especially due to the high similarity of food proteins to inhalation 
allergens (e.g. from birch pollen or house dust mite). Apple allergy, with its widespread 
occurrence in North-West Europe, is a well-known example of a birch pollen related food 
allergy (Ferreira et al., 2004). 
Food allergy diagnosis involves several steps. Skin prick testing with food 
extracts and with fresh foods, the measurement of food specific IgE, elimination diets 
and a double-blind, placebo controlled food challenge are the main diagnostic 
procedures (Patriarca et al., 2009). The diagnostic approach to suspected food 
hypersensitivity reactions begins with the medical history and the clinical examination. 
Skin prick testing provides a rapid method to screen patients with suspected food allergy. 
Detection in serum of a specific IgE is the second step after skin prick tests for the 
diagnosis of food allergy. If these steps indicate potential food allergy, a food challenge 
may be used to confirm the food allergy. Assuming that specific foods are suspected to 
be responsible for an allergic disorder, they can be eliminated from the patients diet, with 
the aim of eliminating the patient’s symptoms and confirming the diagnosis. 
The development of a food allergy can be divided into two phases: sensitisation 
and symptom development (Herz, 2008). The sensitisation phase is characterized by the 
production of an allergen specific IgE antibodies response and their binding to tissue 
mast cells. Subsequent exposure of the sensitised individual to the same allergen, or to 
an immunologically cross-reactive protein, cross-linking mast cell-associated IgEs 
causes degranulation and the release of pre-formed and newly synthesised mediators 
(like histamines). This provokes the local and/ or systemic inflammation reactions 
(Dearman and Kimber, 2009). The latter phase results in structural mucosal changes that 
limit therapeutic options at this disease stage, which is why strategies to prevent the 
onset and the persistence of an allergic manifestation are needed (Herz, 2008). 
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At the time of writing, the only reliable treatment of food allergy is strict avoidance 
of the problematic foods and food ingredients. Food allergy can have a profound impact 
on quality of life, not only because of the immediate clinical effects related to individual’s 
allergic condition, but also because of the alterations in daily life that have to be made to 
prevent the occurrence of symptoms and the influence on psychosocial functioning of the 
individual (Blok et al., 2007; Oude Elberink et al., 2002; Sicherer et al., 2001). 
 
1.2 Food allergy management  
The most important goal of food allergy management is to prevent the 
development of the condition because, when an individual has become food allergic, the 
only treatments are to avoid known allergenic foods and to treat any allergic reaction with 
‘as needed’ medications (Skripak and Sampson, 2008). At the time of writing, 
desensitisation therapies are only usable for a select number of food allergic consumers. 
This means that the only option for many food allergic consumers is to completely avoid 
all foods to which they are allergic (Skripak and Sampson, 2008). 
Many people may play a role in food allergen avoidance. The first are food 
allergic consumers for whom the allergen avoidance is necessary to prevent allergic 
symptoms. Depending on the specific allergy, and how commonly the food is used as an 
ingredient to more food products, this has very broad consequences. The alterations to 
daily life that are made to avoid allergens may also affect the families of food allergic 
consumers (Bollinger et al., 2006; Oude Elberink, 2006). 
Second is the food industry who has a responsibility to produce food that is safe 
for all consumers. Often foods that may have been in contact with allergens are labelled 
with may-contain labelling, which is confusing for food allergic consumers (Cornelisse-
Vermaat et al., 2008b). Third, health professionals and scientists may facilitate allergen 
avoidance by improving information about the disease and its management to food 
allergic consumers. In addition, better diagnostic techniques may lead to a better 
understanding of what foods cause allergic reactions and therefore may lead to more 
accurate allergen avoidance (Mills, 2007). 
Fourth, regulators provide legislation that addresses the safety of foods, which 
includes allergenic safety. The food industry has the responsibility to produce foods that 
are safe for consumers, including food allergic consumers. Improved allergen traceability 
through the food chain may aid consumers with the allergen avoidance (Mills, 2007). The 
development of hypoallergenic foods may also improve allergen avoidance.  
This thesis focuses on allergy management that relates on the one hand to the 
introduction of novel foods which may have hypoallergenic properties, or which can 
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substitute for allergenic foods to facilitate allergen avoidance and therefore may have 
benefits for food allergic consumers. On the other hand, novel foods may have the 
potential to induce new allergies. This issue will also be considered. 
 
1.3 Novel foods 
New foods are continuously being developed and introduced onto the European 
market. Some of these new foods can be regarded as novel foods. In regulatory terms 
(European Commission, 2008a) novel foods are defined as foods or food ingredients 
with no history of widespread and safe consumption. The novelty of a food can be the 
result of:  
(1) genetic modification (GM) of the food itself, or its production using genetically 
modified organisms. Genetic modification is the change of hereditary material by 
transferring properties of one organism (e.g. plant, animal) into another organism 
(Tenbült et al., 2005). 
 (2) the application of novel processing techniques, such as new types of heat 
processing, non-thermal preservation methods and the application of new processes 
catalysed by enzymes,  
(3) the food in question having no prior history of consumption in general, or in a 
specific region or country, such as for “natural” imported foods.  
Novel foods may be associated with positive attributes such as improved yield, 
disease resistance, and prolonged shelf-life. In recent years, many food innovations 
have been targeted at the promotion of good health (Ronteltap et al., 2007). One 
potential benefit of novel foods that may appeal to some consumers is that of 
hypoallergenicity. Food allergic consumers may profit from the availability of 
hypoallergenic novel foods, as well as consumers who have an increased risk of 
developing food allergies. The concept of hypoallergenicity refers to the elimination, or 
removal of the biological activity of allergens. In the case of cow’s milk allergy (CMA) 
hypoallergenic formulas are defined as those tolerated by ≥90% of infants with 
documented CMA who are exposed to the tested formula following an elimination diet 
(Herz, 2008; Lifschitz, 2008). However, it is also important to note that other novel foods 
with new proteins may have the potential to elicit allergenic sensitisation (Lucas et al., 
2004).  
Theoretically, there are three scenarios in which a novel protein may be a risk for 
allergenicity. The first is identity/cross-reactivity with a known allergen, which relates to 
the introduction of a known allergen, or a cross-reactive allergen into a food crop. An 
example of the product of a gene derived from an allergenic source is the Brazil nut’s 2S 
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albumin, an allergenic protein that showed reactivity in Brazil nut allergic consumers after 
its transfer to an experimental GM soybean (Nordlee, 1996). The second scenario refers 
to the potential to increase the endogenous allergenicity of the target (commonly 
allergenic) food due to unintended effects on plant metabolism (that impact on the level 
of expression of endogenous allergens). The risk associated with the introduction of a 
novel gene that affects endogenous levels of allergens is more controversial. It could be 
argued that allergic consumers will be avoiding that food already and therefore are not at 
increased risk. However, increasing levels of an allergenic protein could increase the 
number of individuals who will become sensitized to the allergen (de novo sensitisation). 
This is the third scenario in which a protein may be a risk for allergenicity: the novel 
protein may be a de novo allergen that has not previously been experienced by the 
human population (Dearman and Kimber, 2009). De novo sensitisation to new allergens 
is a legitimate concern, given that the introduction into the diet of conventionally 
produced novel foods, such as that of kiwi fruit in the United Kingdom, has resulted in the 
appearance, and a steady increase in the number of cases of food allergy to this product 
(Dearman and Kimber, 2009). In addition to the risks associated with novel proteins, 
allergenicity of a protein may also be affected when novel processing techniques are 
applied. Food processing may increase or decrease the allergenicity of a protein 
(Thomas et al., 2007). 
 
1.4 Consumer acceptance 
For a novel food to become successful as part of food allergy management, 
consumer acceptance is an absolute requirement. An example of a novel food that has 
failed to reach widespread adoption is food that has been irradiated to increase shelf life. 
Despite the fact that the scientific community recognised food irradiation as an effective 
and safe process, significant consumer resistance has inhibited the application of the 
technology (Behrens et al., in press). 
Societal responses to emerging technologies may be driven by perceptions of 
both risk and benefit. Similarly, consumer decsion-making may be driven by perceptions 
of risk and benefit associated with specific products (Ronteltap et al., 2007). In the case 
of novel foods developed using emerging technologies, it is relevant to consider both 
consumer attitudes to the production technology, as well as the novel product itself 
(Schenk et al., 2008). 
Consumer acceptance of novel foods as part of food allergy management 
strategy is a function of the actual and perceived risks and benefits of the novel foods, 
the type of allergy and the attitudes of the food allergic consumer, and the information 
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available about the specific novel food. In the case of food allergy, uncertainty about the 
extent to which the food is truly hypoallergenic, for food allergic consumers, is highly 
relevant, in particular in the case of allergens which have the potential to provoke severe 
reactions.  
Most information regarding the acceptance of novel foods concerns focus on 
genetically modified foods. A few publications refer to the application of GM to produce 
allergen-free or low-allergen novel foods (Astwood and Fuchs, 1996; Fuchs and 
Goodman, 1998; Mendieta et al., 1997). Using genetic modification for such a purpose 
may be perceived as a benefit by food allergic consumers (Moseley, 2001). Research by 
Miles et al. shows that the intention to purchase genetically modified novel foods with 
specific benefits was higher than the intention to purchase an unspecified genetically 
modified novel food (Miles et al., 2006a). However, these authors report that consumers 
are more likely to purchase low-allergen food produced using conventional methods than 
food produced using genetic modification. Thus a conventional method of production 
may be preferred by consumers (Miles et al., 2006a). None-the-less, low-allergen food 
might represent an attractive benefit for food allergic consumers.  
Given evidence of consumer concern that genetic modification may actually 
cause new food allergies, it may be that even if hypoallergenic food is perceived 
positively by food allergic consumers, the use of genetic modification in the production of 
such food would be regarded negatively (Miles et al., 2006a). This can also be explained 
by the fact that consumers may have different attitudes towards a technology and the 
resulting innovation. 
 
1.5 Aim 
The aim of the research presented in this thesis is to investigate whether novel 
foods can be used as part of an allergy management strategy. For novel foods to be 
used in food allergy management various factors must be considered. These include (1) 
the actual hypoallergenicity of novel foods, (2) consumer acceptance of novel foods in 
general and by food allergic consumers in particular, and (3) the potential impact of novel 
foods on the quality of life of food allergic consumers. Chapter 2 discusses the issues 
associated with novel foods and food allergy, such as societal acceptance of such 
products. The potential issues that arise when applying novel foods as allergy 
management strategy are identified. Chapter 3 describes the results of a stakeholder 
consultation, and of focus group discussions with food allergic consumers. The most 
important food allergy concerns held by both food allergic consumers and stakeholders 
are identified, together with their opinions regarding the potential impact of novel foods 
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as a risk management strategy. Chapter 4 describes the results from surveys among 
food allergic and non-food allergic consumers regarding the acceptance of 
hypoallergenic novel foods and identifies different consumer groups based on attitudes 
towards the application of hypoallergenic novel foods as food allergy management. 
Chapter 5 reviews the international legislation regarding the safety of novel foods to 
determine whether these regulations protect consumer health sufficiently while allowing 
consumers to profit from the potential novel food benefits. Effective consumer protection 
through regulation is an essential part of introducing such foods into the food chain. In 
the final chapter 6, the results and conclusions from the empirical studies are discussed. 
This chapter also addresses the limitations of this research and the implication for future 
research. Figure 1.2 provides an overview of the structure of this thesis. 
 
 
Figure 1.2 Outline of the thesis. 
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Chapter 2 
Novel foods and food allergy: the issues 
 
This chapter is published as: Putten, M.C. van, Frewer, L.J., Gilissen, L.J.W.J., 
Gremmen, B., Peijnenburg, A.A.C.M. & Wichers, H.J. (2006) Novel foods and 
food allergy: A review of the issues. Trends in Food Science & Technology, 17 
(6), 289-299. 
 
Abstract 
This review identifies and explores the current issues around different types of novel 
foods and allergy concerns. An important issue relates to the observation that risk 
estimates associated with novel foods may differ depending on whether more emphasis 
is placed by the individual on the results of technical risk assessment or on an 
individual’s perceptions of risk associated with different hazards. Consumer perceptions 
of benefits associated with novel foods also vary. Perceptions of what constitutes both 
risk and benefit appear to be important determinants of consumer acceptability of 
particular products. One conclusion that can be made is that novel foods have the 
potential to contribute to food allergy management, but that consumer acceptance is 
likely to differ according to the preferences of individual consumers. It is concluded that 
some novel foods may result in improvements on the quality of life of food allergic 
patients, whereas others may result in the development of further socio-economic 
problems.  
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2.1 Introduction 
This review aims to identify and explore issues around novel foods and food 
allergies. A food allergy is defined as an aberrant fast immunological reaction to normally 
harmless food components, usually proteins (Sampson, 1999a). Food allergy is 
distinguished from food intolerance, which is a non-immune-mediated reaction. In 
contrast with food allergy, symptoms of food intolerance can take several days to 
manifest themselves. Novel foods are defined as foods or food ingredients that have no 
history of safe use in the European Union (EU). The absence of a history of safe use can 
be the result of: (1) genetic modification of the food or production of the food using 
genetically modified organisms, (2) novel processing techniques, or (3) the food being 
new to the European Union. That is, although the food has a history of use in other parts 
of the world, this is not the case in Europe. The latter category is in the context of this 
chapter referred to as natural novel foods. 
There is some evidence that food allergy prevalence is increasing in some parts 
of the world, although this is not definitively proven (Helm and Burks, 2000). One aspect 
of food allergy that needs further consideration is that of novel foods. The introduction of 
novel proteins into the food chain and the human diet may result in new cases of food 
allergy. In contrast, the elimination of allergenic proteins may lead to reduced risk of 
allergy. In both cases, consumer and other stakeholder attitudes towards the application 
of novel technologies to food production complicate the issue of commercialisation of 
novel foods. For the purpose of this chapter we will consider food allergy and novel foods 
in the context of the European Union. However, the issues discussed are generic and 
have international applicability.  
Various organisations and individuals have an interest in the issue of food allergy. 
Examples of stakeholder groups are food allergic individuals and their families, health 
professionals, the food industry, policy makers, public health authorities, non-
governmental organisations (NGOs), patient organisations, scientists and finally the 
general public, who may have to deal with the issues associated with food allergy on an 
occasional basis. 
This review chapter will discuss the different risks and benefits associated with 
novel foods within the context of technical risk assessment, as well as public risk 
perceptions regarding the acceptability of different kinds of novel foods. We will then 
discuss food allergy prevalence, which may be on the increase, although the literature is 
varying regarding this issue. Quality of life may be negatively affected by food allergy 
(Sicherer et al., 2001) and also needs to be addressed. In addition, different strategies 
for allergy management and the role novel foods can play in the development and 
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enactment of allergy management will be discussed. Finally, future research needs will 
be identified. 
 
2.2 Novel Foods 
Novel foods may be introduced into the food chain in order to attain some 
associated potential societal or environmental benefits, (Rowland, 2002) but may also be 
associated with some (perceived) risks (Shewry et al., 2000). We provide an overview of 
the risks and benefits associated with novel foods, as both these factors are likely to 
influence the acceptance of novel foods by consumers.  
 
2.2.1 Risks and benefits 
Genetically modified foods 
There is an extensive literature regarding consumer attitudes to the introduction 
of genetically modified foods, particularly in Europe (Frewer et al., 2004). Various factors 
determine consumer acceptance of genetically modified foods, including those relating to 
perceptions of involuntariness of exposure regarding individual consumption, inability to 
trace genetically modified foods and ingredients in the food chain, and perceived 
unnaturalness of food products and production methods. In the area of health, many 
consumer concerns about genetically modified foods are related to the uncertainty of the 
(potentially long term) effects on consumer health in general (Frewer and Salter, 2003; 
Miles and Frewer, 2001) including increased allergenicity associated with the 
introduction of novel proteins into the human food chain (Shewry et al., 2000). An 
example of this is the 2S albumin in the Brazil nut which was used in transgenic soy 
bean, to which some consumers are allergic. 
Although the process of genetic modification may introduce new allergenic 
proteins into foods, it can also be used to remove established allergens (Kuiper et al., 
2002; Shewry et al., 2000). At the present time, it is unknown whether food allergic 
consumers would be willing to buy and use these hypoallergenic foods, or whether 
allergic consumer acceptance would be contingent on the severity of the allergic reaction 
experienced (Schenk et al., 2008). 
Benefits associated with genetically modified novel foods include improved yield, 
enhanced plant disease resistance, improved taste and other quality parameters, and 
improved growth in adverse conditions such as drought and low temperatures (Rowland, 
2002). Many of these benefits are similar to those that have been achieved in 
conventional breeding programs. However, whereas some traditional breeding 
techniques aim at changing as many genes as possible in the plant genotype in order to 
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produce the desired changes, genetic modification permits the expression of the target 
gene(s) alone.  
Consumer’s perceptions of the risks and benefits of genetically modified foods 
influence acceptance or rejection of specific products. Miles et al. (2001) have 
demonstrated that the extent of the accrual of benefits, and to whom these benefits 
accrue, (for example, to industry or consumers) appears to be an important factor in 
consumer acceptance (Miles and Frewer, 2001). To date, most of the advantages 
conferred by genetic modification in the agrifood sector are linked to improvements in 
agronomic traits, which have no direct benefit for consumers. Thus, if we assume that 
consumer acceptance of genetically modified foods is underpinned by consumer 
recognition that there are direct benefits to consumers, it is unlikely that improvement in 
agronomic traits alone will result in consumer approval of novel products (Frewer et al., 
2003b; Miles and Frewer, 2001; Saba et al., 1998). 
Genetic modification of crops may result in novel foods with improved quality 
characteristics, improved nutritional and health attributes, resistance to spoilage and 
even reduced levels of allergens, which have a direct benefit for consumers (Kuiper et 
al., 2002; Taylor and Hefle, 2001). Research by Saba et al. (1998) indicates that some 
consumers would be willing to buy genetically modified foods with consumer oriented 
benefits (Saba et al., 1998). However, at the present time, more research is needed to 
clarify whether consumers would be willing to buy genetically modified foods with 
benefits in terms of reduced allergenicity. 
 
Foods produced using other novel processing techniques 
Examples of processing techniques that are at the time of writing, considered 
“novel” are thermal processing, high-pressure processing, ultra filtration and γ-irradiation. 
All of these techniques have been introduced in order to improve food safety and quality. 
Application of these techniques may reduce or increase allergenicity (Davis et al., 2001). 
For example, the impact of thermal processing on the presence of food allergens 
depends on which specific allergens are present in the food. The major apple allergen, 
Mal d 1, is a protein that degenerates easily following thermal processing. This 
denaturation changes the structure of the protein, which makes it impossible to be 
recognised by immunoglobulin-E (IgE). As a consequence, the consumer does not suffer 
from an allergic reaction to the protein. In contrast, some fish allergens do not produce 
an adverse reaction when the product is fresh, but produce an allergic response after 
these are cooked (Davis et al., 2001; Wigotzki, 2001). Further analysis is required to 
determine systematically which allergens are activated and which ones are eliminated 
during various methods of novel processing. The benefits of novel processing techniques 
 23 
include increasing the shelf life of products without negatively altering structure and 
taste.  
 
Natural novel foods 
The major risk associated with natural novel foods is that they contain proteins 
that may provoke allergic reactions within populations where they have been newly 
introduced into the diet. This increased risk is the result of globalisation and increased 
allergen distribution through the world. Related to this is the risk that the new proteins 
are cross-related to known allergens, or those which are already extant in a particular 
food chain. The major benefit of natural novel foods is the increased diversity of food 
from which consumers can choose and possibly as a consequence, the increase of 
healthy compounds in the diet (Bäckström et al., 2003). 
 
2.2.2 Risk Conflict 
Different individuals appear to evaluate the risks and benefits of novel foods in 
different ways, and this also varies across different applications. Very broadly, it appears 
that there are differences between the way that experts and non-experts evaluate risks, 
an observation established over many different types of hazard (Slovic, 1999). In the 
present discussion, we refer to this difference as risk conflict. 
Technical risk assessments are frequently the basis of risk management 
practices within the risk analysis framework. Technical risk assessments are often used 
by experts and regulators to determine acceptable safety levels (Taylor and Hefle, 2001), 
although consumer decision-making is, in part, based on broader, societally relevant 
factors of concern (Frewer et al., 2004). The latter will be discussed in the next section. 
Assessment of potential allergenicity is, of course, only one component of the risk 
assessment of novel foods (Kuiper et al., 2002; Rowland, 2002). Microbiological and 
toxicological risks are also important, although they are not relevant to the topic of 
allergenicity. 
 
Consumer risk perceptions 
Risk perceptions are a specific form of attitude towards a particular object, such 
as a potential food hazard (Frewer et al., 2004). These include factors such as the extent 
to which an individual perceives the risk of a hazard to be uncertain, dreaded, potentially 
catastrophic, uncontrollable, equitably distributed and presenting risks to future 
generations and influence people’s acceptance of a particular hazard (Slovic, 1999). This 
broad concept of risk implies that psychological responses to a particular hazard may not 
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directly relate to technical risk estimates resulting from a formal risk assessment 
procedure. In contrast, experts tend to see risk as synonymous with probability of harm, 
or expected mortality, consistent with the way in which risk tends to be characterised in 
risk assessment. Therefore, technical risk estimates, traditionally provided by experts, 
influence people’s behaviours in a different way than risk perception (Frewer et al., 
2004). As a result, many conflicts over the risk of foods may result from different 
stakeholders having different perspectives (Slovic, 1999). For example, in the case of 
Starlink maize, most experts estimated the chance of Starlink provoking an allergic 
reaction in human consumers to be very small. Despite these reassurances from the 
expert community, the discovery of Starlink maize in tacos destined for human 
consumption was viewed negatively by the consumer, and consequently resulted in the 
recall of almost 300 maize products (Gremmen et al., 2004). 
People’s responses to risk are psychological, such that people’s perceptions 
about a particular hazard influence their responses to it (Frewer et al., 2004). The social 
context of risk also plays an important role in how people represent risk (Joffe, 2003). 
Social representation theory can provide a useful framework for examining risk 
perceptions of novel foods and the way science enters the domain of everyday thinking 
(Bäckström et al., 2003). Social representations can be defined as systems of relevant 
values, ideas and practices (Moscovici, 2000), and can be used for research focussed 
on the social construction of social knowledge (Flick et al., 2002). Bäckström et al. (2003) 
have demonstrated using social representation theory that the risk perceptions 
associated with novel foods are multidimensional (Bäckström et al., 2003). In other 
words, people make sense of unfamiliar novel foods using various dichotomies, such as 
trust/distrust, safe/unsafe, natural/artificial, pleasure/ necessity and past/present. The 
artificial and unnatural nature of foods produced using genetic modification has been 
identified as an important dimension for consumer negativity towards these products 
(Bäckström et al., 2003). Trust in science and regulators, or a lack of it has been 
identified as a potentially important determinant of consumer acceptance of novel foods 
(Frewer et al., 2003a).  
 
Genetically modified novel foods 
Governmental regulatory agencies in most developed countries require a 
mandatory safety assessment and consultation with governmental regulators before 
commercial sale of genetically modified foods is permitted (Taylor and Hefle, 2001). 
However, the assessment process applied to determine the allergenic potential of 
genetically modified foods presents major problems, since there are no reliable tests for 
predicting clinical allergenicity. As a consequence, assessment of allergenic potential 
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has often focused on determining whether the novel product is substantially equivalent to 
the traditional counterpart (Taylor and Hefle, 2001). The safety of traditional foods and 
ingredients is usually accepted on the basis of their history of safe use. As a 
consequence, there is general consensus that, where possible, safety assessment 
should use traditional foods and ingredients as reference points, and that assessment 
processes should focus on the differences between these traditional foods, and the novel 
foods and ingredients under assessment (Howlett et al., 2003). If a novel food is 
determined to be substantially equivalent, then it is judged to be as safe as its traditional 
counterpart. If the novel food is not substantially equivalent it needs to be subject to a 
broader analysis on a case-by-case basis, with the safety assessment focussing on 
established differences between the novel food and its conventional counterpart (Taylor 
and Hefle, 2001). An established decision-tree approach for predicting the potential 
allergenicity of novel proteins is that of the Codex Alimentarius and the Food and 
Agriculture Organisation / World Health Organisation consultation group. This decision 
tree approach, which assumes that the amino acid sequence is known, is discussed 
frequently in the existing literature (for example, see Taylor et al., 2001). 
Applying this approach provides reasonable assurance that the newly introduced 
protein has limited capability to develop into an allergen (Taylor and Hefle, 2001). 
However, it is important to realise that absolute safety is not an achievable standard, 
since all technologies hold known and unknown risks (Garza and Stover, 2003). This 
uncertainty is one of the risks frequently mentioned by consumers (Miles and Frewer, 
2001).  
When during this risk assessment process no particular concern is indicated for 
any specific population group (not only known food allergic individuals), the occurrence 
of non-immunologically based reactions may still become apparent post-launch. This 
indicates the need for post-launch monitoring (Howlett et al., 2003). It should be noted 
that application of the substantial equivalence approach does not satisfy consumer 
concerns associated with the application of genetic modification more generally. For 
example, a consumer concerned about the potentially negative impact of genetically 
modified crops on the environment, independent of the absence or otherwise of novel 
proteins in foods to be consumed, may not be reassured by claims of substantial 
equivalence of novel foods (Frewer et al., 2004). 
 
Foods produced using other novel techniques and ethnic novel foods 
It should be noted that expert risk assessment focuses on the novel protein as 
unit of analysis, rather than the complete food. This is because a few genes are 
introduced into a particular genome. As a consequence, it remains exactly the same, 
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except for these genes, so it is only necessary to focus on the new protein which results 
from the inclusion of additional genes (Howlett et al., 2003). However, for foods that are 
produced with the use of novel processing techniques, and for natural novel foods, it is 
not sufficient to assess whether a single protein has been produced. In the case of 
various processing techniques it is not effective to assess the amino acid sequence, 
because in most cases the amino acid sequence does not change. Instead, it is the 
protein structure that changes and that reveals or hides an epitope, which is the binding 
site on a protein for IgE. 
In the case of natural novel foods it is not possible to focus on a single protein 
because the product may not have been introduced into a particular food chain before 
and, in the case of foods introduced into the European market, possess a genome that 
has not been described previously. It is therefore not possible to examine the amino acid 
sequence of specific foods, and the decision tree approach cannot be applied to natural 
novel foods. However, in most of these cases, it is possible to identify an established 
food that is similar, either in terms of plant function, or because it has a botanical 
relationship to the natural novel food. It is also possible to screen for known allergenic 
proteins in the natural novel food. These proteins can be compared to known allergenic 
proteins. This means that it is possible to use the substantial equivalence principle, and 
as a result the natural novel food is considered safe if the comparable counterpart has a 
history of safety (Howlett et al., 2003; Kuiper et al., 2002).  
Of course, it is arguable that experts also apply factors other than those grounded 
in rationality (Jensen and Sandøe, 2002). Thus it is important to acknowledge that 
experts apply values to risk assessment, and lay people are capable of reasoning. 
However, experts tend to utilise arguments originating in technical risk assessment to a 
greater extent than do the public in proposing different arguments about risks of novel 
foods (Gremmen et al., 2004). 
 
2.2.3 Novel food acceptance 
In the area of (food) technology innovation, people may tolerate some level of risk 
associated with (for example) production processes if they also perceive direct benefit to 
themselves as consumers, rather than to other groups in society, such as producers or 
the food industry (Frewer, 2003). Scientists and industrialists have, in the past, assumed 
that consumers will accept novel products with a specific consumer benefit. However, 
just as the public, to some extent, defines risk in a different way to experts (Kleef et al., 
2006), it is possible that the public also defines benefits differently. In addition, what is 
perceived to be a benefit associated with a novel food differs between different countries 
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and cultures, and between different individuals at different times and within different 
contexts (Frewer et al., 2004). Genetically modified foods with reduced or absent 
allergenicity may be perceived as highly beneficial by food allergic consumers and thus 
acceptable. For non-allergic consumers, the perceived risks may outweigh the benefits. It 
might be concluded that, as long as risk is not so large as to be completely intolerable, 
an individual’s acceptance will be driven by perceptions of personal benefit (Frewer, 
2003). However, individual differences in attitude, in part shaped by personal needs and 
requirements also need to be taken into account. We can explain the relative 
acceptability of natural novel foods when compared to genetically modified foods. The 
introduction of novel foods from different cultures, may be accepted by a particular group 
of consumers more easily because they have already been “tested” by other people 
(Bäckström et al., 2003), or because they are considered to be natural in origin, and thus 
tolerable. 
There is thus some theoretical evidence regarding the factors which may 
influence consumer acceptance of novel foods, at least in Europe. It remains unclear, 
however, whether consumers will accept novel foods in practice. Technical risk 
assessment processes currently used by risk assessors and regulators is only of partial 
utility in developing a risk communication strategy, as it does not address some 
important consumer concerns. 
 
2.3 Food allergy and society 
It is said that the prevalence of food allergy is increasing (Helm and Burks, 2000). 
In order to assess the extent of the food allergy problem it is important to understand the 
reported prevalence of food allergies. 
 
2.3.1 Food allergy prevalence 
Although the increasing prevalence of food allergy is frequently mentioned in the 
food allergy literature, information regarding formal assessment of the epidemiology of 
food allergy is less often presented (Altman and Chiaramonte, 1996; Crevel, 2002; 
Fraser et al., 2000; Helm and Burks, 2000; Kagan, 2003; Kimber and Dearman, 2002; 
Oehlschlager et al., 2001; Thompson and Chandra, 2002; Zeiger, 2003). Only a few 
articles have reported primary data on food allergy prevalence (Eigenmann et al., 1998; 
Sicherer et al., 1999; Sicherer et al., 2003; Woods et al., 2001). At the present time, it is 
not understood whether the introduction of novel foods will contribute to an increase in 
food allergies, or if genetically modified novel foods with reduced allergenicity will 
significantly reduce food allergy prevalence. This requires close monitoring in the future. 
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Table 2.1 gives an overview of food allergy prevalence for both children and adults 
reported in different literature sources. One distinction that is made in this table is 
between the prevalence of “true” food allergy and “perceived” food allergy. True food 
allergy prevalence refers to the percentage of patients in a population with a formal 
diagnosis of food allergy. Perceived food allergy prevalence refers to the people’s belief 
that they personally exhibit the symptoms of a food allergy, independent of whether a 
health professional would diagnose them as food allergic. This means that the self-
reported data leading to population level estimates of prevalence of perceived food 
allergy may include both food allergy and food intolerance and maybe even other 
adverse reactions to food. This explains why the public’s perception of food allergy 
prevalence may be much higher than is supported by the actual prevalence data. The 
data summarised in Table 1 show that there is no agreement within the existing literature 
regarding the prevalence of food allergy. One of the reasons for this lack of agreement is 
that it is difficult to diagnose food allergy. The Double-Blind-Placebo-Controlled Food 
Challenge (DBPCFC) is both expensive and time consuming for patient and doctor. 
Other diagnosis methods are Radioallergosorbent tests (RAST) in which the amount of 
specific IgE is tested, and skin prick tests (SPT) where glycerinated diluted food extracts 
are applied to the skin by prick technique (Sampson, 1999b). It is important to note that 
there are two phases of food allergy: the primary contact with an allergen and the later 
repetitive contact with an allergen, which results in symptoms (Mills et al., 2003). Some 
individuals become sensitised, but never develop the symptoms. These individuals will 
get positive results from RAST assays and SPT, but a DBPCFC will give negative 
results. Diagnosis is therefore highly dependent on the diagnosis method used, which 
clearly contributes to ambiguities in food allergy prevalence rates. Other diagnosis 
methods available are questionnaires and self-report data. These are not reliable 
methods of food allergy diagnosis because food allergy symptoms are often similar to 
those associated with other adverse reactions to food, (for example nausea), which 
results in a higher reported food allergy prevalence than actually is the case. Another 
problem in developing accurate prevalence estimates is that only a few studies analyse 
food allergy prevalence across complete populations, as opposed to population 
segments. This is illustrated by the study of Eigenmann et al. (1998) who report a food 
allergy prevalence of 37% in a population of children suffering from atopic dermatitis 
(Eigenmann et al., 1998). Although the prevalence in this population could be accurate, it 
makes comparison of prevalence rates with other studies and other populations difficult. 
In addition, there is a lack of uniform definitions of various adverse reactions to food, 
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Table 2.1 Food allergy prevalence 1 
Year1 Prevalence Diagnosis2 Food3 C/A4 Population5 Country6 Source 
28% Parentally reported FA 1980-1984 8% DBPCFC 
No specific 
foods C 
480 children followed prospectively 
from birth to their third birthdays USA (Bock, 1987) 
5.3% Parentally reported FA 
Before1988 1.7% Open food challenge 
No specific 
foods C Infants 0-6 months 
The 
Netherlands 
(Douwes, Weert-Waltman 
van, Folkertsma, Fagel and 
Verboom, 1988) 
12.4% 
Self reported Food 
allergy/ Food 
intolerance 1989-1992 
2.4%7 DBPCFC 
No specific 
foods A Healthy Dutch adults 1483 individuals 
The 
Netherlands 
(Niestijl Jansen, Kardinaal, 
Huijbers, Vlieg-Boerstra, 
Martens and Oc khuizen, 
1994) 
1991-1994 12% Self reported FA/FI No specific foods A 
Cross sectional sample of 17280 
adults aged 20-44 years 
14 European 
countries and 
USA 
(Woods, et al., 2001) 
Before 1994 1.4-1.88 Self reported FI No specific foods A+C 
15000 households (7500 cross 
sectional, 7500 randomly selected 
nationwide 
UK 
(Young, Stoneham, 
Petruckevitch, Barton and 
Rona, 1994) 
0.6% C 4374 households nationwide sample  Children under 18 years 1997 
1.6% 
Self reported allergy Peanut or tree 
nut allergy A 4374 households nationwide sample  
USA 
 
(Sicherer, et al., 1999) 
Before 1998 37% IgE (6 foods) 
Milk, egg, 
peanut, soy, 
wheat, fish 
C 63 patients with atopic dermatitis between 0.4 to 19.4 years USA (Eigenmann, et al., 1998) 
1.2% C 4855 households nationwide sample  2002 1.3% Self reported 
Peanut or tree 
nut allergy A 4855 households nationwide sample  
USA 
 
(Sicherer, et al., 2003) 
0.6% C 5529 households nationwide sample  2002 2.8% Self reported 
Sea food 
allergy A 5529 households nationwide sample  
USA 
 
(Sicherer, Muñoz-Furlong 
and Sampson, 2004) 
                                               
1
 The year in which the study was conducted. 
2
 The diagnosis column refers to the method that was used to diagnose the participants of the study. 
3
 In this column is indicated whether the reported prevalence rate applies to a specific type of food. 
4
 C and A indicate whether the study was focused on children, adults or on both. 
5
 Information about the sample and population the sample was drawn from. 
6
 County in which the study has been done. 
7
 Estimated, based on Double-blind Placebo-controlled Food Challenge and on the assumption that FA/FI is equal among participant, non-participants and drop-outs. 
8
 1.4% with stringent criteria and 1.8% with less-stringent criteria. 
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resulting in problematic interpretation of research findings. The effect of this can be seen 
in the third column of Table 2.1 where the definitions of food allergy used in patient 
diagnosis vary across research studies. There is, however general agreement that the 
prevalence of food allergy in children is higher than in adults (Altman and Chiaramonte, 
1996; Bock, 1987; Chandra, 1997; Crevel, 2002; Kimber and Dearman, 2002; 
Sampson,1999a). The greater prevalence in children can be explained by an increased 
predisposition of children to develop food allergy, and by the tendency for children to 
develop immunologic tolerance as they get older.  
However, due to the incomparability of the data presented in table 1 it is not 
possible to conclude that food allergy prevalence has increased. The only studies that 
show a small increase in peanut and tree nut allergy prevalence are those of Sicherer et 
al. who found a slight increase in prevalence in children of over five years of age 
(Sicherer et al., 1999; Sicherer et al., 2003). However, there is some indirect evidence 
that indicates that food allergy prevalence is increasing. The first indication for this 
increase is cross sensitisation, which means that food allergy often occurs in 
combination with other allergies. It has been established that the prevalence of other 
allergic diseases such as pulmonary or occupational allergies is increasing, which 
suggests that the prevalence of food allergy might be increasing in line with this general 
trend (Jansen and Brussaard, 2001). Another indication of increased prevalence is 
provided by the observation that peanut allergy is becoming more common in younger 
generations, but not in older ones (Hourihane et al., 1996). Since peanut allergy is rarely 
outgrown, it can be expected that peanut allergic children will continue to suffer from 
peanut allergy as they get older. The third indication is the fact that, as a consequence of 
the increase of global trade, the variety of food consumed at the present time is higher 
than in the past. As a result, people will be increasingly exposed to a wider diversity of 
food antigens, which may result in increased food allergy (Fraser et al., 2000; Jansen 
and Brussaard, 2001). 
 
2.3.2 Socio-economic impact 
Food allergies can have a significant impact on the quality of life and economic 
functioning of people who suffer from them, as well as wider implications for society more 
generally. The economic impact of food allergy is composed of both direct and indirect 
costs. Direct costs include both medical and non-medical expenses associated with the 
disease, such as prevention and treatment costs and transportation costs associated 
with healthcare provision (Gergen, 2001). Indirect costs are linked to factors such as 
work and productivity. The introduction of novel foods with reduced allergenicity may be 
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readily accepted if these foods have a positive effect on quality of life and economic 
functioning. However, it is unlikely that improvements in socio-economic functioning of 
food allergic patients in isolation of other societal benefits will facilitate global marketing 
of foods previously confined to specific ethnic groups or geographical locations, because 
such benefits only apply to a limited number of people. The economic impact of food 
allergy is difficult to estimate because of a lack of knowledge about the population-level 
prevalence. In addition, a cost for one stakeholder group may represent a benefit to 
another stakeholder group. In the case of allergy, for example, medication will result in 
costs for patients or insurance companies, but generate profits for the pharmaceutical 
companies. Patients will, of course, also benefit from alleviation of symptoms (Mugford, 
2004). In the European White Paper on Allergy (1997) the socio-economic costs of 
allergy have been estimated. The total costs of the major allergic diseases (including 
allergic rhinitis, allergic asthma, atopic dermatitis, contact dermatitis and urticaria) are 
estimated at 10 billion ECU for direct costs and 19 billion ECU for indirect costs. Food 
allergy is not mentioned as one of the major allergic diseases in this report, perhaps 
because of the paucity of information available to permit cost estimation regarding direct 
and indirect costs (Aas et al., 1997).  
Generally speaking, the costs of food allergy are conceptualised in different ways 
by different stakeholder groups within society. If the economic costs are assessed by risk 
regulators and public health authorities, one might expect that both direct and indirect 
costs are considered important, and thus should be taken into account when 
implementing a strategy regarding the commercialisation of novel foods, whether from 
the perspective of allergy reduction, or reducing any potential for increased prevalence of 
food allergy. From the food manufacturers and retailers point of view, the direct costs 
tend to carry greater weight, because they tend to influence the cost of business 
activities. From an industrial perspective, indirect costs are of less importance as quality 
of life is not a direct issue. The liability of food manufacturers regarding hidden allergens 
in products is an increasingly relevant issue, as liability claims can have an impact on 
direct costs of food manufacturers if labelling is inaccurate (Crevel, 2002).  
The indirect costs of food allergy have a much greater impact on individuals and 
families, because these costs reflect the functioning and quality of life of the individual 
and the family where a family member suffers from a food allergy (Gergen, 2001). The 
social impact of food allergy primarily relates to potentially negative effects on quality of 
life (QoL). Food allergy can have a profound impact on quality of life, not only because of 
the immediate clinical effects related to individual’s allergic condition, but also because of 
the alterations in daily life which are needed in order to prevent the occurrence of food 
allergy symptoms and the influence on psychosocial functioning of the individual 
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(Sicherer et al., 2001). Reactions that can occur when a food allergic individual is 
exposed to allergens range from abdominal pain, vomiting and/ or diarrhoea to 
cardiovascular symptoms, including hypotension, vascular collapse and cardiac 
dysrhythmias. Exposure to a food allergen can even result in anaphylaxis, which may be 
severe enough to be life-threatening (Sampson, 1999a). Thus food allergy may result in 
restriction of social activities (for example, eating outside the home, more problematic 
shopping expeditions) and anxiety (Knibb et al., 2000). The only reliable therapy used to 
treat food allergy at the present time is restriction or complete elimination of the 
responsible food allergen and emergency management of reactions in case a food 
allergen is accidentally ingested. Needless to say, this has a negative impact on the 
quality of life of both the food allergic individual and their families (James, 2001), as well 
as an emotional impact (Meltzer, 2001), and psychological distress (Knibb et al., 1999), 
and restrictions on leisure activities and other lifestyle factors (Knibb et al., 2000). Whilst 
labelling is informative (Crevel, 2002), and essential for consumers with a diagnosed 
food allergy (Mills et al., 2004), the introduction of novel allergens may result in allergic 
responses independent of a labelling policy, as individuals will not know to which foods 
and ingredients they will experience negative reactions.  
2.4 Management of food allergies 
2.4.1 Prevention 
An important step of food allergy management is prevention. Zeiger (2003) 
identifies three phases of prevention, primary, secondary and tertiary. Primary prevention 
essentially means blocking of immunologic sensitisation and thus reducing the 
prevalence. Secondary prevention is interpreted as suppression of disease symptoms 
after immunologic sensitisation has occurred. Tertiary prevention represents the stage in 
which symptoms are treated and worsening of the patients situation is prevented (Zeiger, 
2003). 
 
Primary prevention 
Primary prevention appears to be beneficial only for infants with an atopic family 
history (Zeiger, 2003). A critical time in early infancy can be identified in which the 
genetically programmed atopic infants are at higher risk to become sensitised to 
ingested and/or encountered food allergens. Prenatal exposure may also be problematic 
in terms of sensitisation. Some novel foods can help in primary prevention as they do not 
expose the child to potential allergens. However, it cannot be assumed that all food 
allergens are already identified. This means that it may not be possible to avoid the yet 
unidentified food allergens. This could be the case with natural novel foods, since their 
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amino acid sequence is, in most cases, unknown. In addition, it is difficult to identify in 
advance which proteins in novel foods could cross-react with known allergens. Predictive 
testing of food to identify allergens is a method of primary prevention, because it enables 
risks to be identified, which is the basis for control, but this procedure cannot identify the 
risk of cross-reactions (Smith, 1997). Thus primary prevention of food allergy should 
focus not only on food allergens, but also on the avoidance of allergens that are not 
directly causing food allergy, but might do so due to cross sensitisation, as is the case 
with birch allergens. 
 
Secondary prevention 
Once sensitisation has occurred, avoidance of the food allergens is the only proven 
strategy to prevent the occurrence of symptoms. Strict elimination diets may lead to 
malnutrition, especially if they include a large number of foods and/or are used for 
extended periods of time (Sampson, 1999b). Elimination of a single food can be difficult, 
especially when the food is used in many other food products, such as milk. Labelling is 
an important part of secondary prevention because it enables individuals to avoid foods 
to which they are already hyper-sensitised (Smith, 1997). A prerequisite for this is that 
the information on the label is readily understood by the consumer (Crevel, 2002). 
It should be noted that there is a difference between treatment of a disease and life-long 
avoidance (Kilshaw, 1981). In case of food allergies, the impact of avoidance on the daily 
lives of food allergic consumers and their families forms a major part of the socio-
economic problems associated with food allergy. Avoidance is therefore not a real 
solution for the food allergy problem, although it currently is the most important part of 
food allergy management. Novel foods can help with secondary prevention because their 
potential for inducing allergic responses may be reduced.  
 
Tertiary prevention 
Given the difficulty of avoiding food allergens, it must be assumed that patients may 
experience accidental ingestion of problematic foods. Contamination with an unrelated 
food during the manufacturing process or misrepresentation of a food item on a label are 
common causes of accidental exposure to known allergens (Thompson and Chandra, 
2002). Medications, such as anti-histamines, have been used in an attempt to modify 
symptoms of food-induced allergic disorders, but overall they have minimal efficacy. Oral 
corticosteroids are generally effective in treating chronic IgE-mediated disorders, but side 
effects are generally unacceptable to patients (Sampson, 1999b). In case of anaphylaxis, 
injection of epinephrine is the primary treatment, even in the early stages before the 
onset of life-threatening symptoms, as treatment failure is more likely if epinephrine is 
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delayed (Thompson and Chandra, 2002). Children with symptomatic food allergy often 
lose their allergy over time. Exceptions tend to occur in most cases of peanut, tree nut, 
and seafood allergy (Sampson, 1999b). Consequently, food challenges should be 
repeated at set intervals to determine whether the dietary restrictions are still necessary 
(Bruijnzeel-Koomen et al., 1995).  
Tertiary prevention involves medication of symptoms and therefore it is unlikely that 
novel foods can play a role in tertiary prevention. 
 
Conclusion 
It is obvious that primary prevention, the prevention of sensitisation, is the best 
strategy to decrease the food allergy prevalence, because this type of prevention 
reduces the socio-economic impact on the daily lives of food allergic consumers and 
their families. Secondary prevention does not really prevent allergic disease, but only 
prevents the occurrence of symptoms. In an ideal situation secondary prevention is not 
necessary, because primary prevention would have proven to be successful. Given that 
tertiary prevention is nothing more than treatment of the symptoms, it still represents an 
important part of food allergy management, as these symptoms can be severe, or even 
fatal. 
2.4.2 Novel foods applied to food allergy management 
The incidence of severe (and potentially fatal) food-induced allergic reactions 
indicates that current management strategies (allergen avoidance and early use of 
epinephrine) are not adequate for dealing with food allergies (Leung and Bock, 2003), 
suggesting that additional management strategies are needed. Novel foods may facilitate 
food allergy management. One approach under investigation involves the mutation of 
IgE binding epitopes on major peanut proteins. The mutated recombinant protein may 
desensitise patients with peanut allergy in a manner similar to standard immunotherapy 
without the risk of inducing anaphylactic symptoms (Sampson, 1999b). Another 
approach under investigation involves the development of hypo-allergenic foods. In 
these foods, most allergens have been removed chemically, enzymatically or by 
formulating the food product from different ingredients. For example, rice has been 
genetically modified to suppress the expression of a gene encoding for a certain allergen 
(Laiho et al., 2002). However, it is unlikely that all consumers will accept the introduction 
of genetically modified rice into the food chain, particularly those not suffering from food 
allergy. However, allergic consumers may be enthusiastic about these novel foods, 
resulting in the development of niche markets for hypoallergenic food products.  
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Differences in the neonatal gut micro biota may precede the development of 
atopy. The modification of the gut micro biota by means of novel foods induces beneficial 
effects that may reduce the risk of allergic disease (Nowak-Wegrzyn, 2003). Allergic 
disease could be prevented through nutritional management capable of preventing or 
depressing allergic inflammation based on the administration of novel foods containing 
strains of beneficial microbes (Laiho et al., 2002). However, again the issue of product 
acceptability based on consumer response may need to be addressed.  
2.5 Conclusions 
In this review we have identified various issues surrounding novel foods and food 
allergy. An important issue is that there are both risks and benefits associated with novel 
foods. Consumer acceptance of novel foods is contingent on both technical risk 
estimates, and consumer perceptions of both risk and benefit. Furthermore, consumers 
are not homogenous, and what is perceived as a desirable benefit by one consumer may 
be regarded as irrelevant by another. In the case of novel foods, genetic modification 
directed towards reducing allergenicity may be viewed positively by allergic consumers, 
but is unlikely to meet with general consumer approval. This suggests that such products 
should be marketed specifically to consumers who want to buy them, under conditions of 
fully informed consumer choice.  
Consumers perceive ethnic novel foods are less risky than genetically modified 
foods (Bäckström et al., 2003). However, the example of kiwi fruit proves that natural 
novel foods cannot be considered safe from an allergy point of view without proper 
safety analysis (Bublin et al., 2004; Lucas et al., 2004). 
It can be concluded that novel foods, despite some risks, have the potential to 
contribute to food allergy management. They can contribute particularly to primary and 
secondary prevention by avoidance of the concerning allergens. For tertiary prevention, 
novel foods are less helpful. However, novel foods can also potentially increase the 
prevalence of food allergy through introduction of novel or unlabelled allergens into the 
human food chain, and this needs to be carefully assessed. It remains unclear what are 
the allergy risks for novel foods that are not genetically modified, perhaps indicating the 
need for implementation of a decision tree similar to that applied to genetically modified 
novel foods. 
 
Acknowledgements 
This literature review has been done as part of a PhD project funded by the Allergy 
Consortium Wageningen, The Netherlands. 
 36 
 37 
 
Chapter 3 
Stakeholder and consumer views regarding novel hypoallergenic 
foods 
  
This chapter is accepted for publication as: Putten, M.C. van, Gilissen, 
L.J.W.J., Gremmen, B., Peijnenburg, A.A.C.M., Wichers, H.J. & Frewer, 
L.J. (in press) Stakeholder and consumer views regarding novel 
hypoallergenic foods. British Food Journal 
 
Abstract 
The development and introduction of novel hypoallergenic foods represents a 
potential approach to reducing the negative health impacts of food allergy. The aim of 
this research is to assess whether novel hypoallergenic foods will be accepted by food 
chain actors and consumers. Stakeholder opinions (collated using semi-structured 
interviews, N=16) regarding the acceptability of novel hypoallergenic foods were 
assessed. Three focus groups (one comprising anaphylactic food allergic consumers, 
and two comprising consumers with less severe food allergies) were applied to 
understand the opinions of food allergic consumers. Food allergic consumers expressed 
a preference for a “cure” for food allergy. However, they acknowledged that 
hypoallergenic foods had the potential to improve the quality of lives of food allergy 
suffers through increasing dietary variation, and reducing restrictions on product 
selection. Stakeholders supported the introduction of novel foods (although this support 
was not universal), assuming the products were acceptable to food allergic consumers, 
consumers in general, and regulators. The results cannot be extrapolated to the general 
population because of small sample sizes. However, the results are indicative of 
potentially important factors determining societal acceptance of novel hypoallergenic 
foods in the future. The issue of whether such novel foods would be acceptable to non-
food allergic consumers was not addressed. The chapter is likely to be useful for the 
potential developers of hypoallergenic foods allergen food products (food industry and 
scientists) and policy makers regarding the commercialisation of novel hypoallergenic 
foods and their regulation.  
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3.1 Introduction 
Food allergy represents an increasing concern to society. Food allergy is defined 
as an inappropriate immunological reaction to normally harmless food components and 
affects 5-8% of children and 1-2% of adults (Buttriss and Schenker, 2002; Rona et al., 
2007; Sicherer et al., 2001). Food allergies potentially have a negative impact on the 
quality of life (Blok et al., 2007; Sicherer et al., 2001) and economic functioning of food 
allergic patients (Cornelisse-Vermaat et al., 2008b; Fernandes-Rivas and Miles, 2004; 
Fox et al., in press) and may also result in substantial costs for society overall in terms of 
health care costs and absenteeism (Blok et al., 2007; Miles et al., 2005). The only 
effective treatment for food allergy available at the time of writing is for food allergy 
sufferers to avoid problematic foods (Ortolani and Pastorello, 2006), which may 
negatively influence the psychosocial functioning of both the individual and their families 
(Blok et al., 2007; Primeau et al., 2000; Sicherer et al., 2001). For example, food allergy 
may result in restriction of social activities (including eating outside the home, attending 
social events, more time expended in shopping for food) and experience of anxiety 
(Gowland, 2001). 
Hypoallergenic foods are currently being developed (for example, through 
application of genetic modification), which could facilitate food avoidance and therefore 
improve the quality of life of food allergic consumers (Hoffmann-Sommergruber and 
SAFE-consortium, 2005; Lorentz et al., 2006). Several examples exist of genetically 
modified foods with reduced levels of allergenic proteins, such as rice (Nakamura and 
Matsuda, 1996), soybean (Herman et al., 2003), apple (Gilissen et al., 2005), peanuts 
(Dodo et al., 2005), and tomato (Lorentz et al., 2006). However, genetic modification is 
not the only approach which can be applied to the development of hypoallergenic foods 
and ingredients. Other novel processing techniques, such as high pressure processing 
or extreme heat application, may reduce the allergenicity of problematic foods and 
ingredients (Davis et al., 2001). Novel ‘natural foods’ and food ingredients are new to 
and have no history of safe use in the European Union. Both “technological” (Davis et al., 
2001) and ‘natural novel’ foods (Lucas et al., 2005) may exhibit reduced allergenicity and 
therefore they may contribute to allergy mitigation. This chapter discusses three types of 
novel foods: genetically modified novel foods (GM) , technological novel foods and 
‘natural’ novel foods. All three types can be hypoallergenic, but they also might introduce 
new allergic responses by inserting novel proteins into the food chain (Taylor and Hefle, 
2001). 
The question arises as to whether these various novel products are acceptable to 
both food allergic consumers (Frewer et al., 1997; Schenk et al., 2008) and relevant 
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actors in the food chain (Putten et al., 2006). If novel hypoallergenic foods are to result in 
improvements to public health, they must be accepted by both stakeholders and 
consumers (Cornelisse-Vermaat et al., 2008b). As stakeholder opinion is likely to 
influence societal debate about the risks and benefits of these novel food products, 
understanding the opinions of key stakeholders is highly relevant (Putten et al., 2006). 
Consumer perceptions regarding the risks and benefits of novel foods are also likely to 
influence acceptance or rejection of specific products (Miles and Frewer, 2001). The 
introduction of genetically modified foods into the European food chain has resulted in 
consumer negativity in the past (for example, see Frewer at al, 2004). The introduction of 
novel foods as a solution to food allergy problems may not be universally accepted by 
non-allergic consumers, who will not directly benefit from their introduction (Schenk et al., 
2008). Furthermore, whilst novel foods with reduced allergenicity have some benefits for 
food allergic consumers as the introduction of novel foods might reduce or alleviate the 
allergenicity of problematic ingredients (Gilissen et al., 2005; Kuiper et al., 2002), there is 
also the potential risk that new proteins are introduced into the human food chain, which 
may increase allergic reactions, or introduce new allergic responses (Taylor and Hefle, 
2001). 
If novel foods are to be included as part of a food allergy as allergy mitigation 
strategy, acceptance by food chain actors and consumers is required. It is generally 
believed that experts think about food risks differently from members of the public (Fife-
Schaw and Rowe, 1996; Krystallis et al., 2007). Experts and regulators often use 
technical risk assessments to determine acceptable safety levels in general and food 
allergy in particular (Taylor and Hefle, 2001) whereas consumer decision making is, in 
part, based on broader societally relevant factors of concern, such as the extent to which 
an individual perceives the risk of a hazard to be uncertain, dreadful, potentially 
catastrophic, uncontrollable, equitable distributed and presenting risks to future (Frewer 
et al., 2004; Slovic, 1999). Optimising a public health policy regarding the introduction of 
novel hypoallergenic foods is contingent on both stakeholder and consumer acceptance 
of novel foods and associated production processes where relevant. 
The aim of this chapter is to gain insight in the potential impact of hypoallergenic 
novel foods on public health issues associated with food allergy, as well as potential 
barriers to their introduction, by comparing the perspectives of both food allergic 
consumers and relevant actors in the European food chain. The views of key 
stakeholders must be systematically evaluated in order to predict potential societal 
responses to novel hypoallergenic foods. Important stakeholders include food industry, 
public health authorities, scientists and health professionals. Acceptance of novel 
hypoallergenic foods is contingent on acceptance by both stakeholders and consumers. 
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Stakeholder behaviour regarding novel foods should be relevant to consumer opinions 
and expectations. 
It should be noted that the research is exploratory in nature and the intention was 
not to test a particular theoretical perspective, but to begin to gather knowledge about 
which risks, costs and benefits associated with novel foods and allergies may inform the 
societal debate about their introduction in the future. The research aims to answer the 
question as to whether novel foods can be used as allergy mitigation strategy, which is 
contingent on both stakeholder and consumer assessments of the hypoallergenic foods 
themselves, as well as the production processes used to develop them in the case of 
potentially controversial food technology applications. 
3.2 Methodology 
 In the description of methodology that follows, the term stakeholder will be used 
to describe all stakeholders other than consumers, for reasons of clarity. The stakeholder 
analysis aimed to identify stakeholder opinions about novel foods applied as part of a 
food allergy mitigation strategy. Stakeholders included different food chain actors who 
have interests in the development and introduction of novel foods, or food allergies, or 
both as part of their professional lives These stakeholders answered questions during 
the course of semi-structured qualitative interviews. Representatives from these 
stakeholder groups were recruited through established contacts, based on their 
(hypothesised) expertise. A cascade methodology was applied, such that stakeholder 
recommendations for further stakeholders to include in the analysis were utilised in 
further recruitment. Further recruitment of stakeholders into the study ceased when the 
information obtained during the interviews became theoretically saturated i.e. when no 
further new information was obtained from additional interviews. In total 16 European 
stakeholder representatives were interviewed: three health professionals, three food 
industry representatives, three public health authority representatives, three scientists, 
two representatives from non-governmental organisations and two from patient 
organisations. These stakeholder categories were selected in line with those identified in 
a previous stakeholder analysis relevant to food allergy issues (Miles et al., 2006b). The 
list of questions was sent to stakeholders in advance, to allow participants to prepare for 
the interview, and to consult with colleagues if appropriate. All stakeholder 
representatives were recruited within Europe. The interviews, conducted by the same 
interviewer, took place between February 2005 and February 2006, and were conducted 
by telephone or in person when the travel distance permitted. The interviews were 
recorded for transcription purposes. Respondents were given the opportunity to 
comment on the transcript of the interview before further analysis took place. 
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Table 3.1 Demographic characteristics of the focus group participants 
Characteristics Category N  
Male 1 
Female 18 
Gender 
Total 19 
17-249 4 
25-34 5 
35-44 7 
45-54 0 
55-64 2 
>65 1 
Age 
Total 19 
Full-time 5 
Part-time 4 
Pensioner 2 
Student 4 
Homemaker 1 
On disability allowance 1 
Different 2 
Working status 
Total 19 
Low 1 
Medium 7 
High 11 
Education level 
Total 19 
(Pea)nuts 11 
Egg 1 
Milk 5 
Shellfish 3 
Fish 1 
Soy 3 
Celery 1 
Allergy10 
Sesame seed 2 
General practitioner 3 
Specialist 9 
Self 8 
Diagnosis11 
Other (homeopath/ kinesiotherapist) 4 
 
In order to compare the views of food chain actors with food allergic consumers, 
additional research using focus group methodology was conducted using food allergic 
consumers. Considering that the topic of discussion, novel foods, is new to most food 
allergic consumers, focus group discussions were the most suitable method for data 
                                               
9
 Parental permission to participate to the focus group discussion was obtained for the 17 year old 
participant. 
10
 Multiple allergies in one person are calculated as separate allergies. 
11
 Multiple diagnosis for one person are calculated as separate diagnosis. 
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collection. This method allowed participants to develop and explore their opinions on 
novel foods through group interactions under the guidance of a moderator more 
effectively than using semi-structured interviews. To determine the opinions of food 
allergic consumers, three focus group discussions were held in January and February of 
2007 in Wageningen, The Netherlands. Participants were recruited via a newspaper 
advertisement, message boards in supermarkets, and an announcement on the intranet 
message board of Wageningen University and Research Centre (WUR). As for the 
stakeholders, a cascade recruitment methodology was used, such that participants were 
asked to invite other food allergic of food intolerant consumers to the focus groups. 
Between five to eight food allergic or food intolerant consumers participated in each 
focus group, which were lead by the same moderator. One focus group included only 
anaphylactic food allergic consumers, whereas the other two focus groups were 
comprised of food allergic consumers, who experienced less severe food allergic 
reactions (see table 3.1 for demographic and diagnostic analysis). 
The focus group discussions utilised the same protocol, which was approved by 
Wageningen University ethical committee. After an introduction round, a free association 
task followed during which the participants wrote down the three most important food 
allergy problems on three pieces of paper. This resulted in an overview of the food 
allergy problems according to the participating food allergic consumers. The participants 
then discussed what should be to improve the food allergy problems they had previously 
identified. These problems were used to start the discussion about novel foods. Prior to 
the discussion, novel foods were defined and examples were provided. The focus groups 
lasted approximately 90 minutes. After participation in the focus group, participants 
received a 20€ gift certificate. Following the agreement of participants, the focus group 
discussions were audio recorded for transcription purposes.  
 
3.3 Results 
This section presents the results from both the stakeholder analysis and the focus 
group discussions. First the results from the stakeholder analysis are presented, followed 
by the presentation of the focus group discussion. Comparison of the stakeholder and 
consumer views is made, and some conclusions regarding the overall acceptability of 
novel foods as mitigation strategies for food allergy discussed. 
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Stakeholder analysis 
All stakeholders perceived some potential contribution from novel foods to the 
prevention of food allergy occurrence. An important barrier to the introduction of such 
novel foods related to practical implementation.  
Health Professional 212: ”I think the potential is perhaps when modifying the 
protein structure of food, so that the allergenic part is eliminated. It’s an exciting idea. 
And I think that it could help in theory. In practice it may be difficult, because it may be 
hard to identify a genetically modified, and therefore safe, food compared to the original 
version.” 
Some stakeholders stated that hypoallergenic novel foods may provide an 
alternative for allergenic food products and ingredients and offer a wider food choice to 
food allergic consumers. However, stakeholders stressed that consumer acceptance of 
these novel foods was an important determinant of whether their introduction would be 
successful or not. 
Scientist 3: ”Well, I think if you could introduce novel foods that are not going to 
cause an allergic reaction, so that people who have allergy can have a wider choice so 
that there might be an alternative to them for the food they are allergic to, then that might 
be something that would improve their quality of life. But I think what you need to do is to 
make sure or to look into whether people with food allergy would be prepared to eat 
novel foods.” 
The stakeholders tended to associate novel foods with solutions to the problem of 
food allergy, although potential increases in food allergy incidence were also identified. 
The latter were mainly theoretical, and have not yet been observed in practice: for 
example, stakeholders postulated that novel foods can contain existing or novel 
allergens or that novel processing techniques may change protein folding revealing new 
epitopes, which are the binding sites for IgE. 
Food Industry representative 1: “Maybe these genes can produce a protein which 
causes another reaction [to that] expected.” 
While it may be technically possible to develop novel foods that are hypoallergenic or 
which do not provoke an allergic reaction in some food allergic consumers, some 
stakeholders did not consider the introduction of hypoallergenic novel foods as a realistic 
option throughout the relevant food chains. This was because only a minority of the 
population is affected by specific food allergies. In addition, the introduction of novel 
proteins into the food chain in itself may be problematic, as consumers may develop 
allergies to the novel proteins following long-term effect of exposure. In particular, natural 
                                               
12
 The number refers to a specific individual in this stakeholder group. 
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novel foods were described as actually causing new problems, as they cause allergic 
reactions. 
Public Health Authority representative 1: “Kiwi is a good example of a natural 
novel food that can be allergenic.” 
There may be unexpected effects that cannot be foreseen at the present time. For 
example, some stakeholders thought the introduction of novel foods could result in more 
allergies, increased allergenicity of the food or allergenic gene expression in the case of 
genetic modification if new or existing allergens are introduced into the human food 
chain. 
Health Professional 2: “Well, I think novel foods could increase problems if there 
is not enough legislation or testing of them… in theory that can cause problems 
as well.”  
Other stakeholders thought existing regulatory systems and testing methods were 
sufficient to protect consumers from the risks of novel foods. 
Public Health Authority representative 2: “Yes, potentially they could increase 
problems, but that of course relies on the risk assessment that we do. I think the 
regulation is so strict that we will not allow products [to be introduced] when we are 
in doubt. But of course you could imagine some kind of technological change of the 
food, which we cannot predict that enhances allergenic potential of the food.” 
In summary, most stakeholders believe that novel foods can, in theory, contribute to a 
solution for the food allergy problems they described, because they are potentially less 
allergenic and therefore may represent a safe alternative for allergenic food consumers. 
Natural novel foods are only a good alternative when the products are proven safe, but 
initially stakeholders considered them more as a cause of consumer’s food allergy 
problems. The stakeholders also mentioned some potential problems when novel foods 
are introduced, such as consumers who develop allergies to the novel proteins in novel 
foods. Of course, novel foods can only have these benefits if consumers are willing to 
buy them. 
 
Focus group discussions 
Food allergic consumers reported that the best way to influence the food allergy 
problems would be through reduction or elimination of the symptoms of food allergy. If 
food allergic consumers experienced mild symptoms, or no symptoms, after eating foods 
to which they are allergic, they would not need to invest so much effort in avoiding the 
consumption of allergenic proteins. Shopping would take less time, and eating outside 
the home would be less troublesome, as measures would not be needed to prevent 
accidental exposure to allergens. Social restrictions would also be reduced. Whilst many 
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participants expressed the view that they would be in favour of novel hypoallergenic 
foods being developed and commercialised doubts were expressed regarding whether 
the novel foods really would be less allergenic. This illustrates that participants in the 
focus groups doubted whether novel foods potentially reduced their allergenicity. Doubts 
were also expressed more directly. 
13B1: “I do not believe this at all.” and C5: “I do not believe that [the food industry] 
they would put the consumer’s interest first. “ 
Consumers perceived that novel foods could only be used for allergy reduction 
when all food ingredients are replaced across all food chains. For example, if a less 
allergenic variety of wheat could be found, this could be beneficial for consumers who 
are intolerant of gluten because this would allow them to consume products that contain 
wheat, but only if the new variety was used in all products containing wheat. However, 
this view was expressed that such comprehensive introduction of the new variety across 
all food chains may not be feasible. In addition, the food allergic consumers included in 
the study indicated that they would only trust novel hypoallergenic novel foods to be safe 
to consume following positive experience with specific products.  
B7: “You just have to try them. If you never try something new, you will also never 
find a solution to your problem.”  
B6: “I trust that these foods can be further developed and that they can provide 
substantial mitigation.” 
One difference between people with immediate allergic symptoms and people with 
symptoms that appear later, (for example, as in the case of food intolerance such as 
celiac disease) is that the latter are less willing to experience the potentially beneficial 
effects of the novel foods. The reason for this is that those consumers could suffer 
intestinal damage before they notice that they still react to the novel wheat. People with a 
severe food allergy stated that they would not want to consume novel hypoallergenic 
foods. Thus the perceived severity of the allergic reaction experienced by specific 
consumers influences the likelihood that consumers will try novel hypoallergenic foods. 
In addition, reducing the allergen content of a food product was thought not be sufficient 
for consumers who respond to small amounts of the problematic food. This led to the 
conclusion that food allergic consumers differed in their opinion depending on the 
specific food allergy and on the sensitivity (threshold level) of the allergic individual. In 
addition, consumers indicated that the easier it was to avoid consumption of a particular 
                                               
13
 The three different focus group discussions are indicated with either, A, B or C. The number 
refers to a specific individual participating in one of these focus group discussions. For example, 
consumer C5, refers to food allergic consumer number 5 in the third focus group discussion. 
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food, the less was the perceived need to develop substitutes in the form of novel foods. 
For example, there was more acceptance of products that are often used as an 
ingredient such as milk. 
C4: “I can imagine that using a novel food as substitute for a product that is an 
ingredient for many other products would be better than when it substitutes a 
product that is consumed directly.” 
However, consumer demands for sensory experience should not be neglected. Some 
food allergic consumers stated they would like to eat certain foods again. 
A5: “It would be great if I could eat red beets again.” 
This implies that care should be taken to avoid changing the sensory characteristics of a 
food if allergenicity is reduced. Another advantage perceived by consumers was that by 
consuming these novel foods that contain less allergens, the consumer would be 
exposed to fewer allergens, which would prevent or delay the development of new 
allergies. 
 Food allergic consumers also identified problems with the labelling of novel foods 
when they are used as an ingredient in other products, as they would have to look on the 
package to identify what type of ingredient (traditional or novel) was used. The problem 
would even be exacerbated in the case of ‘may contain labelling’, (Cornelisse-Vermaat et 
al., 2008a; Cornelisse-Vermaat et al., 2008b) as it would be even more difficult to 
estimate what the risk is of the product containing traces of the allergenic ingredient 
actually is, as one could not estimate whether the potential contamination is from 
traditional or hypoallergenic ingredients, as well as the issue of whether the novel foods 
would be more expensive.  
B4: “Then you get labelling that says: ‘this product has been produced in a factory 
where allergenic peanuts are processed.’…and if it is possible to separate the allergenic 
peanuts from the non allergenic peanuts, then you will pay ten Euros for a package of 
non allergenic peanuts.” 
 The focus group participants worried about the changes that genetic modification 
would cause to the product as a whole. 
A4: “I am afraid that the peanut will change in so many ways that it is no longer a 
peanut.” 
To summarise, food allergic consumers would be in favour of novel hypoallergenic foods 
being developed and commercialised. However, they do have doubts about whether the 
novel foods would be less allergenic. Consumers perceived that novel foods could only 
be used for allergy reduction when all food ingredients are replaced across all food 
chains completely. Food allergic consumers with immediate symptoms are more willing 
to experience the potential benefits of novel foods than consumers with symptoms that 
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appear later. Another advantage of hypoallergenic novel foods according to the food 
allergic consumers is that these novel foods could prevent or delay the development of 
new allergies because the consumers are exposed to reduced levels of allergenic 
proteins. 
 
3.4 Discussion 
The results of the study suggest that both food allergic consumers and experts 
associate advantages and disadvantages with the introduction of novel hypoallergenic 
novel foods and their utility as part of a risk management strategy for food allergy. Food 
allergic consumers considered the inappropriate immune response to be the main cause 
of the food allergy problems. They find it unlikely that novel foods will contribute to a cure 
for food allergy. Only one stakeholder had same opinion. However, both food allergic 
consumers and experts could see some contribution of novel foods to allergy mitigation. 
Novel foods could have some mitigating influence on allergy symptoms by limiting the 
exposure to allergens, the “tertiary prevention of food allergy” (Zeiger, 2003). An 
acceptable example might be when a natural hypoallergenic variant of an allergenic food 
exists which can introduced into the food chain. Focus group participants did express 
some doubts about whether novel foods could really be less allergenic. In addition, the 
consumers stated that, if novel hypoallergenic foods are to be accepted by consumers, 
the taste and price need to be similar to their traditional counterparts. The experts 
mentioned that for novel foods to be successfully applied as an allergy mitigation 
strategy, they need to be accepted by consumers. The experts did not specify the 
requirements that need to be met for food allergic consumers to accept novel foods. 
 The food allergic consumers did not express a preference for more natural types 
of novel food over genetically modified novel foods. The perceived benefits and the 
influence on daily life was more important to them than production process per se. This is 
in contrast with the quantitative analysis provided by Schenk et al. (2008) who report that 
food allergic consumers are less tolerant of novel food processing applied to the 
development of hypoallergenic foods if the allergic symptoms are mild (Schenk et al., 
2008). This may, in part, be due to the emphasis of the research presented here, which 
did not seek to examine how food allergic consumers make trade-offs between 
perceived risk and benefit of production technologies, but rather “framed” the research in 
the context of specific benefits to food allergic consumers. The stakeholders thought it 
more likely that genetically modified and technological novel foods can contribute to food 
allergy mitigation than natural novel foods. 
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Limitations of the research 
The results cannot be extrapolated to the general population because of small 
sample sizes. In particular, further research using quantitative methodology and larger, 
more representative samples of food allergic and food intolerant consumers, is required. 
The question of acute and chronic negative responses to foods, and how this interacts 
with acceptance of novel foods also required further research. Finally, the issue of 
societal acceptance of hypoallergenic ingredients produced by novel food processing 
technologies must be addresses in the context of general consumer acceptance, not just 
that of food allergic consumers. However, the results are indicative of potentially 
important factors determining societal acceptance of novel hypoallergenic foods in the 
future. 
 
3.5 Conclusions 
Both consumers and stakeholders expressed some enthusiasm for the 
introduction of truly hypoallergenic novel foods, with the caveat that evidence was 
required to assess whether the novel products were reliably hypoallergenic and still have 
all the same product characteristics as the “traditional” allergenic product. As well as 
rigorous risk assessment, post market surveillance would be required to test whether the 
novel products were indeed hypoallergenic and could be consumed by all consumers 
who were allergic to them. The need for “guarantees” of hypoallergenicity increased with 
the severity of the allergic response following consumption.  
In addition, food allergic consumers feared that eventually they would develop an 
allergy to the novel foods because their immune system is the cause of the food allergy. 
The stakeholders indicated that some benefits of novel foods for food allergic consumers 
could be identified, although systematic risk assessment would be required prior to any 
market introduction. It is notable that both consumers and stakeholders questioned 
whether the novel foods were truly less allergenic. This again indicates the need for 
rigorous (allergy) risk assessment of hypoallergenic novel foods, together with an 
appropriate regulatory structure developed to optimise consumer protection associated 
with potential introduction of novel hypoallergenic foods (Putten et al., submitted). 
Whilst the results suggest that novel hypoallergenic foods have the potential to increase 
the dietary variation available to food allergic consumers, consumers expressed the view 
that a “cure” for food allergy is preferred over substitution of existing foods with 
hypoallergenic allergenic counterparts. 
Societal acceptance of novel hypoallergenic foods will depend not only on the 
fact that the novel foods are hypoallergenic, but also on the severity of the allergic 
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response should it occur. Whilst societal demand for foods used as ingredients, as 
opposed to whole foods which are easily avoided by consumers, is a priority for all 
participants in the study, their widespread inclusion in the food chain will be dependent 
on rigorous demonstration of their safety for all food allergic consumers. This is 
particularly important given that differences in severity of allergic response (for example 
potentially fatal reactions to peanut proteins). Finally, the introduction if novel production 
processes such as genetic modification of foods was not problematic for consumers in 
this study, However the widespread introduction of genetically modified ingredients (as 
opposed to whole foods) still requires further consideration, as they will be consumed by 
non-food allergic consumers who will not derive personal benefits from their 
consumption. 
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Abstract 
Food allergies may have a negative impact on the quality of life and the economic 
functioning of people who suffer from them, as well as the society in which they live. 
Food allergy is defined as inappropriate immunological reaction to normally harmless 
food components. Hypoallergenic novel foods may improve quality of life of food allergic 
consumers when they are accepted by both food allergic and non-allergic consumers. 
This study identifies different consumer groups depending on their attitudes towards the 
risks and benefits of novel foods and their acceptance. In addition, the influence of 
information about the impact of food allergy on the lives of food allergic consumers, and 
about the potential benefits of novel foods on novel food acceptance among non-food 
allergic consumers is identified. A cluster analysis was used to form groups of similar 
consumers. To test the influence of information on novel food acceptance among non-
food allergic consumers an experiment was conducted. 
The results showed that four distinct consumer groups could be identified based 
on their hypoallergenic novel food attitudes and acceptance. The group that was least 
likely to accept hypoallergenic novel foods, was the group with most food allergic 
consumers. This indicates that the application of novel foods as an allergy management 
strategy is complicated because many of the consumers who are supposed to 
experience benefits of these novel foods are less likely to use the novel foods. 
Information about the impact of food allergy on the lives of food allergic consumers, and 
about the potential benefits of novel foods appeared to improve acceptance of these 
novel foods among non-food allergic consumers.  
 
 52 
4.1 Introduction 
Food allergy, an inappropriate immunological reaction to normally harmless food 
components, affects 5-8% of children and 1-2% of adults (Buttriss and Schenker, 2002; 
Rona et al., 2007; Sicherer et al., 2001). Food allergies may have a negative impact on 
the quality of life (Fernandes-Rivas and Miles, 2004) and the economic functioning of 
people who suffer from them, as well as the society in which they live (Fox et al., in 
press; Miles et al., 2005; Voordouw et al., 2009). Quality of life is ‘the individual’s 
perception of their position of life in the context of culture and value systems in which 
they live and in relation to their goals, expectations, standards and concerns’ (WHO, 
1993). Caregivers of a food allergic child could develop some degree of anxiety and 
protectiveness given the potential for severe reactions and the lack of control (real or 
perceived) in some food consumption situations (Bollinger et al., 2006; Primeau et al., 
2000). Food allergy potentially affects meal preparation activities in the home, social 
activities (for both parents and children), may be associated with anxiety, and have a 
detrimental affect on school attendance. The time and effort that it takes to provide a 
safe environment for food allergic children has potential to cause a significant impact on 
daily life. Children who suffer from more than two food allergies report lower quality of life 
scores, a similar experience to that of their parents. 
The only effective treatment for food allergy available at the time of writing is for 
food allergy sufferers to avoid the problematic foods (Ortolani and Pastorello, 2006) 
which may limit food choices, or social and travel opportunities (Oude Elberink, 2006; 
Sicherer et al., 2001). They may even avoid situations, which are potentially harmful. 
This means that food allergic consumers may have to alter their style of living, which may 
have a negative impact on the families of food allergic consumers’ (Bollinger et al., 
2006). 
Various approaches to solving the problems associated with food allergy are 
currently under development. A prominent example is the development of novel 
hypoallergenic foods, developed for example through the application of novel processing 
technologies such as genetic modification, more traditional techniques such as selective 
breeding, or through introduction of novel foods not hitherto used in the food chain 
(Hoffmann-Sommergruber and SAFE-consortium, 2005; Putten et al., 2006; Schenk et 
al., 2008) In the context of the European regulatory framework, novel foods are foods or 
food ingredients with no consumption history in the European Union. The absence of a 
history of safe use can be the result of: (1) genetic modification (GM) of the food or 
production of the food using, genetically modified organisms, (2) novel processing 
techniques, or (3) the food being novel to the European Union.  
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The introduction of novel foods as an approach to food allergy management may 
be ambiguous. On one hand, there is the potential risk that new proteins are introduced 
into the human food chain together with the novel foods (Taylor and Hefle, 2001), which 
may increase allergic reactions. Against this, there are the potential benefits for food 
allergic consumers as the introduction of novel foods might reduce their allergenicity  
(Dodo et al., 2008; Kuiper et al., 2002; Moseley, 2001). However, the extent to which 
consumers accept these novel foods also needs to be understood if they are to be 
introduced into the food chain. Successful commercialisation of hypoallergenic products 
may be contingent on the extent to which consumers perceive benefits to be associated 
with hypoallergenic novel foods. It can be expected that food allergic consumers are 
more likely to accept novel foods than non-food allergic consumers because 
hypoallergenic novel foods may have benefits for consumers with a food allergy. In 
addition, non-food allergic consumers who are informed about the benefits of 
hypoallergenic novel foods could be more likely to accept novel foods than non-food 
allergic consumers without such information. Perceived benefits associated with food 
production technologies such as GM may be important in determining public acceptance 
of both the technology and its products. However, public reactions will be determined by 
a combination of risk and benefit perceptions (Rowe, 2004). Other factors, such as 
perceived “naturalness” of food products, and perceptions of the “need” for new 
products, may also determine acceptance (Tenbült et al., 2005). People’s preference for 
“naturalness” appears to be greater for food compared to other sectors, for example for 
medicines (Rozin et al., 2004). This information is important for the developers of low 
allergen food products (food industry and food scientists) and policy makers to ensure 
that the needs of the allergic consumers are met, benefiting these consumers and the 
food industry (Miles et al., 2006a). However, the introduction of novel foods and 
ingredients may raise other individual and societal concerns (Frewer et al., 2004), which 
may reduce consumer acceptance. In addition, the extent to which hypoallergenicity is 
certain may influence consumer acceptance (Schenk et al, in preparation). Consumer 
attitudes towards novel consumer products need to be identified if the use of novel foods 
is to be accepted as a strategy for food allergy management. 
The aim of the research presented here was to identify different consumer groups 
based on attitudes towards the application of hypoallergenic novel foods as food allergy 
management. Additionally, the influence of information about the impact of food allergy 
on the lives of food allergic consumers, and about the potential benefits of novel foods 
on novel food acceptance among non-food allergic consumers is identified. 
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4.2 Methodology 
 
4.2.1 Participants and research design 
First, both food allergic and non-food allergic consumers were classified based on 
novel food attitudes and novel food acceptance. Data were collected using a panel of 
food allergic and non-food allergic consumers. The food allergic consumers were 
selected using the selection questions presented in annex A. Respondents who reported 
an allergy to peanut, nut, fruit, fish or shellfish, and had avoided these foods for more 
than one year, were invited to participate in the study. Data were also collected from a 
panel of Dutch non-food allergic consumers who were excluded from the study as if they 
self-reported experiencing a food allergy. Representativeness of the panel for the Dutch 
population was derived from quota sampling on the basis of region, gender, household 
income, and age. Table 4.1 shows the demographic characteristics and reported food 
allergies of the sample14. In total 438 respondents participated in the research: 199 
consumers who self-reported experiencing a food allergy, and 239 consumers who did 
not report having a food allergy. There are no missing data. 
After the consumer groups have been identified, an experiment was conducted with the 
non-food allergic consumers to test whether information about the impact of having a 
food allergy and about novel foods benefits influences acceptance of these 
hypoallergenic novel foods. To test this a two-by-three experimental design was used. 
The non-food allergic consumers were randomly divided into two groups. One group 
received information about the impact of having a food allergy on daily life and about 
novel foods and their benefits, the other group received neutral information about food in 
general. (See annex B and C for the information that was provided to the two groups of 
non-food allergic consumers.) Both groups answered questions about three types of 
hypoallergenic novel foods.  
 
                                               
14
 It should be noted that the allergy prevalences in this table do not reflect the range and 
prevalence of food allergies experienced by the food allergic population in the Netherlands. Respondents 
were selected on the basis having a nut allergy, a shellfish allergy or a fruit allergy. This was done to ensure 
larger numbers of respondents with similar allergies to make statistical comparisons possible. 
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Table 4.1 Demographic characteristics of the sample 
Characteristics Category Food allergic consumers 
N (%) 
Non-food allergic consumers 
N (%) 
Male 47 (23.6) 116 (48.5) 
Female 152 (76.4) 123 (51.5) 
Gender 
Total 199 (100) 239 (100) 
18 – 24 11 (5.5) 15 (6.3) 
25– 34 33 (16.6) 38 (15.9) 
35– 44 47 (23.6) 59 (24.7) 
45 – 54 57 (28.6) 46 (19.2) 
55 - 64 32 (16.1) 38 (15.9) 
>65 19 (9.5) 43 (18.0) 
Age 
Total 199 (100) 239 (100) 
Full-time 67 (33.7) 93 (38.9) 
Part-time 55 (27.6) 69 (28.9) 
Unemployed 5 (2.5) 3 (1.3) 
Pensioner 19 (9.5) 36 (15.1) 
Student 3 (1.5) 6 (2.5) 
Homemaker 28 (14.1) 20 (8.4) 
On disability 
allowance 
17 (8.5) 8 (3.3) 
Other 5 (2.5) 4 (1.7) 
Working status 
Total 199 (100) 239 (100) 
Low 48 (24.1) 91 (38.1) 
Medium 77 (38.7) 89 (37.2) 
High 74 (37.2) 59 (24.7) 
Education level 
Total 199 (100) 239 (100) 
<700  47 (23.6) 54 (22.6) 
700 -1500  64 (32.2) 76 (31.8) 
1500 – 2300  48 (24.1) 58 (24.3) 
2300 – 3100  6 (3.0) 17 (7.1) 
3100 – 4100  5 (2.5) 3 (1.3) 
>4100 1 (0.5) 0 (0) 
Undisclosed 28 (14.1) 31 (13.0) 
Household 
income 
Total 199 (100) 239 (100) 
Peanut 51 (25.6)   
Nut 102 (51.3)   
Milk 31 (15.6)   
Egg 10 (5.0)   
Wheat 7 (3.5)   
Soy 12 (6.0)   
Sesame seed 13 
 
(6.5)   
Fish 20 (10.1)   
Shellfish 95 (47.7)   
Celery 6 (3.0)   
Fruit 69 (34.7)   
Vegetables 18 (9.0)   
Other 37 (18.6)   
Allergy15 
Total 471    
                                               
15
 Multiple allergies on one person are calculated as separate cases. 
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4.2.2 Methods and Materials 
Surveys were administered in September 2008 by a social research agency. 
Consumers’ risk and benefits perceptions, and acceptance of hypoallergenic novel were 
measured. Food allergic consumer benefit perceptions were measured with the 
statements: ‘the benefits of hypoallergenic novel foods for me personally are…’, and ‘the 
benefits of hypoallergenic novel foods for the average person in the Netherlands are…’ 
Food allergic consumer risk perceptions were measured with the statements: ‘the risks of 
hypoallergenic novel foods for me personally are…’, and ‘the risks of hypoallergenic 
novel foods for the average person in the Netherlands are…’. Both risk and benefit 
perceptions were measured on a 7-point Likert scale where 1 indicates low benefit/risk 
perceptions and 7 indicates high benefit/risk perceptions. Acceptance of novel foods was 
measured with the statements: ‘I would buy genetically modified novel foods with 
benefits for my allergy if they are similar in taste and price as conventional products’, ‘I 
would buy technological novel foods with benefits for my allergy if they are similar in 
taste and price as conventional products’, and ‘I would buy natural novel foods with 
benefits for my allergy if they are similar in taste and price as conventional products’. The 
measure for GM attitudes in general was previously developed and validated by Frewer 
et al. (Frewer et al., 1997). This GM attitude measure contained 17 items, which included 
“risky”, "long term effects", "dangerous", "harmful", "personal worry", "tampering with 
nature", "personal objections", "creation of inequalities", "negative welfare effects” 
"unnatural", “beneficial”, “advantageous”, “necessary”, “important”, “progressive” 
“unethical”, and “immoral”. These items were translated into Dutch. The translated items 
were tested in the pilot study. Acceptance was measured on a 7-point Likert scale where 
1 indicates no acceptance and 7 indicates very high acceptance. In each questionnaire 
the GM attitude measure items were the last to be completed. The order in which the 
items were presented was randomised. Before completing the GM attitude measure 
items, respondents were given a definition of GM, previously used by Frewer et al. 
(1997). The GM definition was translated into Dutch as well.Non-food allergic consumer 
benefit perceptions were measured with the statements: ‘the benefits of hypoallergenic 
novel foods for food allergic consumers are…’, and ‘the benefits of hypoallergenic novel 
foods for the average person in the Netherlands are…’ Non-food allergic consumer risk 
perceptions were measured with the statements: ‘the risks of hypoallergenic novel foods 
for food allergic consumers are…’, and ‘the risks of hypoallergenic novel foods for the 
average person in the Netherlands are…’ Both risk and benefit perceptions were 
measured on a 7-point Likert scale where 1 indicates low benefit/risk perceptions and 7 
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indicates high benefit/risk perceptions. Non-food allergic consumer acceptance of novel 
foods was measured with the statements: ‘Genetically modified novel foods with benefits 
for food allergic consumers should be made available in stores’, ‘Technological novel 
foods with benefits for food allergic consumers should be made available in stores’, and 
‘Natural novel foods with benefits for food allergic consumers should be made available 
in stores’. In addition to the novel food acceptance also GM attitudes in general were 
measures. GM attitudes of the non-food allergic consumers were measured using the 
same scale as for the food allergic consumers, previously developed by Frewer et al. 
(1997). 
 
4.2.3 Data analysis 
Ward’s hierarchical clustering method was used to identify groups of consumers 
for which the individual differences between the groups dominate the differences within 
the groups (Kornelis et al., 2007). The novel food acceptance items, the risk and benefit 
items, and the aggregated scores on the GM scales served as a classification basis. An 
optimal number of consumer groups was based on the agglomeration schedule following 
inspection of the results. Subsequently the clusters “were fine-tuned” using the non-
hierarchical K-means clustering method. Significant differences between these different 
consumer groups regarding the descriptive and classification variables were assessed 
by means of F-tests. 
The data were analysed using SPSS. Factor analysis was used to derive a 
measure for GM acceptance. The rotated (Oblimin, correlation -0.52) two factor solution 
(PCA) explains 65.5% of the variance. These two components have Eigenvalues higher 
than 1. The first component, which explains 55.1% of the variance loads heavily on 
“risky”, "long term effects", "dangerous", "harmful", "personal worry", "tampering with 
nature", "personal objections", "creation of inequalities", "negative welfare effects", and 
"unnatural". This component could be labelled as “rejection”. The second component 
explains 11,5% of the variance and loads heavily on “beneficial”, “advantageous”, 
“necessary”, “important”, “progressive” and also on “unethical” and “immoral”. The 
loadings on “unethical” and “immoral” are negative. The second component could be 
labelled “acceptance”. The third component has an Eigenvalue below 1. Therefore this 
factor is not taken into account. For further analysis the two aggregated factors for GM 
attitude have been used instead of the 17 items. Cronbach’s α is 0.92 for the “rejection” 
factor and Cronbach’s α is 0.90 for the “acceptance” factor. 
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4.3 Results 
4.3.1 Consumer classification 
A cluster analysis was performed to identify similar groups of consumers based 
on novel food attitudes and their acceptance of novel foods. Four different consumer 
groups were identified on the basis of the cluster analysis. The consumer groups differ 
significantly on the dependent variables that were used to distinguish the consumer 
groups. The variables used to cluster the consumers included the following: Individual 
novel food benefits and risks, general novel food benefits and risks, GM novel food 
acceptance, non-GM technological novel food acceptance, natural novel food 
acceptance, and two GM attitude measures). The consumer groups also differed from 
each other in terms of whether they reported having a food allergy or not. In addition, the 
consumer clusters were compared in terms of demographic factors (age, gender, 
education level, occupation, household income, and household size), but significant 
differences between the clusters were not identified for these variables.  
 
Table 4.2 Mean ratings (standard deviation) of the significant classification variables 
 Pro novel food 
consumers 
Benefit 
contingent 
consumers 
Negative 
consumers 
Uncommitted 
consumers 
Statistics 
Individual novel 
food benefits 
5.17 (1.49) a 5.08 (1.44) a 3.68 (1.52) b 4.95 (1.12) a F=14.38 
df=3, 219 
p<0.0001 
General novel 
food benefits 
3.74 (1.27) a 4.60 (1.38) b 3.91 (1.28) a,b 3.49 (1.09) a F=5.24 
df=3, 219 
p=0.002 
Individual novel 
food risks 
2.29 (0.94) a 4.24 (1.09) b 1.95 (1.05) a 3.51 (1.13) c F=44.36 
df=3, 219 
p<0.0001 
General novel 
food risks 
1.99 (0.90) a 4.48 (0.82) b 2.82 (1.18) c 2.90 (1.16) c F=35.04 
df=3, 219 
p<0.0001 
GM acceptance 6.09 (0.87) a 6.04 (0.89) a 2.11 (1.07) b 3.77 (1.09) c F=195.45 
df=3, 219 
p<0.0001 
Technological 
acceptance 
6.25 (0.76) a 6.00 (0.87) a 2.34 (1.07) b 4.64 (0.98) c F=201.62 
df=3, 219 
p<0.0001 
Natural 
acceptance 
6.30 (0.73) a 6.08 (0.86) a 3.23 (1.40) b 4.88 (0.93) c F=104.89 
df=3, 219 
p<0.0001 
GM rejection 3.76 (1.02) a 4.04 (1.07) a,b 4.31 (1.07) b,c 4.68 (0.88) c F=10.50 
df=3, 219 
p<0.0001 
GM acceptance 4.52 (0.95) a 4.11 (1.17) a,b 3.29 (0.96) c 3.62 (0.80) 
b,c
 
F=17.40 
df=3, 219 
p<0.0001 
Note: All p values < 0.05 for all associated F-tests. The classification variables that share the same 
superscripts indicate cluster means that are not significantly different following Tukey’s HSD test (all p values 
< 0.005) 
Table 4.2 provides a summary of the mean ratings on the variables (measured on 
a 7-point scale) that differ significantly between the clusters. The first cluster consists 
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mainly of non-food allergic consumers. 48 (69.6%) Consumers in this cluster do no suffer 
from a food allergy. The second cluster also contains a majority of consumers without a 
food allergy. Sixteen (64.0%) consumers in this cluster do not have a food allergy. 
Cluster three consists mainly of food allergic consumers. Forty-five (80.4%) consumers 
in this cluster suffer from one or more food allergies. The fourth cluster consists mainly of 
non-food allergic consumers. In this cluster, forty-six (63.0%) of cluster members do not 
suffer from a food allergy. All consumers have a higher level of acceptance of “natural” 
novel foods compared to non-GM technological novel foods, which in turn is higher than 
their acceptance of GM novel foods. Based on these results the following profiles for the 
four consumer groups can be described: 
1. Pro novel food consumers (n=63). Together with the “benefit contingent 
consumers”, consumers in this cluster do not suffer from a food allergy (69.9% = 42 
non-food allergic consumers) and tend to be positive about hypoallergenic novel 
foods. Consumers in this group perceive the benefits of hypoallergenic novel foods to 
be high and the risks to be low. 
2. Benefit contingent consumers (n=25). The majority of the consumers in this cluster 
do not suffer from a food allergy (64.0%, 16 non-food allergic consumers). They 
perceive the individual benefits of hypoallergenic novel foods as high and the risks as 
average, compared to the consumers in the other clusters. These consumers report 
that they accept novel foods if they used as food allergy management strategy. 
3. Negative consumers (n=56). The food allergic consumer group (with 80.4% = 45 
allergic consumers) had the lowest scores on both individual novel food risks and 
benefits. Their willingness to buy the three types of novel foods was lower compared 
to even the non-food allergic consumers. In contrast to expectations, food allergic 
consumers were less likely to accept novel hypoallergenic foods than non-food 
allergic consumers. A possible explanation is that the food allergic consumers are 
more cautious regarding the consumption of new foods, adopting a risk avoidance 
strategy, even if these risks are not perceived to be high. 
4. Uncommitted consumers (n=73). This group consisted of primarily non-food 
allergic consumers (63.0% = 46 non-food allergic consumers). These consumers 
perceive high levels of benefit perceptions and low levels of risk to be associated with 
novel foods, in a way similar to the “pro novel food and benefit contingent 
consumers”, but they are less accepting of novel foods as a potential allergy 
mitigation strategy compared to consumers in this cluster. 
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4.3.2 Novel food acceptance among non-food allergic consumers 
A total of 239 non-food allergic consumers answered questions about their 
acceptance of novel foods. One hundred and twenty one of these non-food allergic 
consumers received information about the impact of food allergy on the daily lives of 
food allergic consumers. The 118 non-food allergic consumers in the control group 
received neutral information about food. Both groups answered the same questions. 
Table 4.3 shows the means for acceptance of the three types of novel foods by 
consumers who had received information about the consequences of suffering from a 
food allergy and hypoallergenic novel foods, and consumers without such information. 
Acceptance was measured on a 7-point likert scale where 1 indicates no acceptance and 
7 indicates very high acceptance. 
 
Table 4.3 Acceptance of different types of novel foods in the experimental and control group 
Food allergy info group Neutral info group  
Mean (Std. dev) Mean (Std. dev) 
Genetically modified novel foods 4.90 (1.73) a 3.72 (1.70) a 
Non-GM technological novel foods 5.34 (1.47) b 4.53 (1.46) b 
Natural novel foods 5.48 (1.29) b 4.99 (1.42) c 
Novel foods (total) 5.24 (1.50) 4.41 (1.53) 
The novel food types that share the same superscripts (column wise) indicate means that are not 
significantly different following Tukey’s HSD test (all p values < 0.005) 
 
The differences in novel food acceptance between consumers with information 
about the impact of food allergy on daily lives of food allergic consumers and consumers 
without such information were significant (F=23.7; df=1, 237; p<0.0001). This indicates 
that non-food allergic consumers who receive such information are more likely to accept 
hypoallergenic novel foods than consumers who do not receive such information. 
Analysis of variance for an effect of novel food type on acceptance shows a significant 
difference as well (F=39.9; df=2, 236; p<0.0001). 
Information about food allergies and its consequences for people who suffer from 
them increased acceptance of novel hypoallergenic foods by non-food allergic 
consumers. Note that both consumers with information about food allergy and consumer 
without such information are more positive towards natural novel foods than non-GM 
technological novel foods. Similarly both groups are more accepting of non-GM 
technological novel foods than of GM novel foods. These findings imply that 
communication about the impact of food allergy on daily lives of people with a food 
allergy may help to accept the introduction of these novel foods by non-food allergic 
consumers who do not receive direct benefits from the novel foods themselves. 
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 An interaction between the type of novel food and the information provision on 
the acceptance of novel foods was also observed (F=8.064, df=1,609, p=0.01). Figure 
4.1 shows the acceptance of the three types of novel foods by the two groups of non-
food allergic consumers. This effect indicates that the type of novel foods becomes less 
important in determining acceptance of novel foods when the benefits are 
communicated. 
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Figure 4.1 Non-food allergic consumer novel food acceptance 
4.4 Discussion 
 
The present study examined the consumer attitudes towards novel foods as food 
allergy management strategy. The empirical results indicate that four distinct consumer 
groups can be identified, which are characterised by different attitudes towards risks and 
benefits of novel foods, GM attitudes in general, and whether participants suffer from a 
food allergy. Twenty-five percent (56) of the consumers are somewhat negative about 
the application of novel foods as allergy mitigation strategy. Seventy-five percent of the 
consumers do not have a food allergy and their attitudes towards novel foods vary from 
being neutral (neither positive nor negative) about the applications of novel foods to 
being positive about them. Of the participants with the more negative attitudes, 45 were 
food allergic. Among the more positive consumers, 57 report a food allergy. These 
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results imply that the application of novel foods as an allergy management strategy is 
complicated because many of the consumers who are supposed to experience benefits 
of these novel foods are less likely to use the novel foods. Almost fifty percent (44.1%) of 
the food allergic consumers in the sample are reluctant to accept novel foods as an 
allergy mitigation strategy, although they perceive hypoallergenic foods to be associated 
with some benefits and low risks. This implies that universal replacement of potentially 
hypoallergenic foods in the food chain is unrealistic. However, the development of niche 
products to meet the demands of some food allergic consumers is indicated as possible 
way forward in the commercialisation of hypoallergenic foods, although further research 
is required to assess whether, for example, acceptance is inversely related to the 
potential severity of an allergic response should it occur (Schenk et al., 2008). In any 
case, naturally occurring hypoallergenic foods appear to be viewed more positively 
compared to those developed through application of emerging technologies. 
A further point relates to developing a communication strategy about novel 
hypoallergenic foods. Some non-food allergic consumers appear to be more positive 
about novel hypoallergenic foods after they have received information about the potential 
problems experienced by food allergy sufferers, This implies that communication 
regarding the benefits of the novel foods might influence societal acceptance about novel 
foods in a positive direction, although this should also take account of differences in 
societal concerns about the potential use of different technologies on food production 
(Schenk et al., 2008).  
Overall, consumer acceptance of novel foods is greater for those which occur 
naturally compared to those produced using emerging agri-food technologies, (a finding 
that is in line with previous research, see for example Rozin et al., 2004 and Tenbült et 
al., 2005). However, even the acceptance of natural novel foods is low among the food 
allergic consumers. People’s preferences for natural food appear outweigh their potential 
advantages for health. This may, of course, vary according to the extent to which the 
potential novel food delivers a benefit or a mitigation strategy which cannot be managed 
through application of alternative strategies, such as avoidance, and is a topic worthy of 
future research.  
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Annex A: Selection Questionnaire for food allergic consumers 
1. Are you allergic to any food(s)? 
 No 
 Yes 
 
2. For which food(s) are you allergic? (Multiple answers are allowed) 
 Peanut 
 Tree nuts 
 Milk 
 Egg 
 Wheat 
 Fruit 
 Vegetables 
 Soy 
 Sesame seed 
 Fish 
 Crustaceans 
 Celery 
 Other food(s), namely 
 
3. Have you stopped eating/drinking this food(s)? 
 No 
 Yes 
 
4. How long ago have you stopped eating/ drinking this food(s)?  
 0 to 6 months ago 
 6 to 12 months ago 
 1 to 2 years ago  
 More than two years ago 
 
5. Which symptoms occurred during the most severe allergic reaction ever? (Multiple 
answers allowed) 
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 Itching mouth 
 Itching throut 
 Itching ears 
 Itching tongue 
 Itchins lips 
 Swelling of the tongue 
 Swelling of the lips 
 Running nose 
 Stuffed up nose 
 Sneezing 
 Itching eyes 
 Running eyes 
 Red eyes 
 Sweling of the throat 
 Difficulty swallowing 
 hoarseness 
 Difficulty breathing 
 stuffiness 
 Wheezing 
 Coughing 
 Itching skin 
 Redness of the skin 
 Swelling of the skin 
 Hives 
 Increased eczema 
 Nauseous 
 Stomach cramps 
 Vomiting 
 Diarrhoea 
 Dizziness 
 Black out 
 Faintness 
 Lightheaded 
 Feinting 
 Other, namely…… 
 None of the above 
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Annex B Information for food allergic consumers regarding food allergy and novel 
foods 
 
If it happens to you: food allergy 
By Maartje van Eerd 
 
Imagine kissing your boy friend and the next minute you are beeing wheeled off to a 
hospital because apperently you are alleric to peanuts. Every year this happens to some 
people. It also happened to Wendy (25) when she kissed her new boy friend. He had just 
eaten a portion sized bag with peanut M&Ms. Wendy is allergic to peanuts, which is a 
severe type of food allergy. 
 
When someone is allergic to food, the body’s immune system produces antibodies 
against proteins that are present in food, such as cow’s milk, wheat, fruit, egg, fish, tree 
nuts and peanuts. Normally, the body does not produce antibodies against these 
proteins. Symptoms of a food allergy vary from eczema, stomach cramps, and swelling 
of the lips to more severe reactions such as an anaphylactic shock and sometimes even 
death. Approximately 8% of children and 2% of adults have one or more food allergies. 
People with a food allergy have to avoid all foods that contain the proteins to which they 
are allergic because currently no cure exists. For Wendy this means avoiding all 
peanuts, which is difficult because peanuts are used as an ingredient for many different 
foods. ‘In When I go out for my shopping, I have to check every product label to check 
the ingredient lists to make sure I do not accidentally eat something that contains 
peanuts,’ explains Wendy. ‘Even a product that is not supposed to contain peanuts, but 
which is produced in a factory that does process peanuts, can be dangerous for me.’ 
Wendy’s parents noticed Wendy reacted badly to some foods when she was young, but 
did not know exactly what was wrong with her. When Wendy was four years old, she ate 
a peanut at a birthday. She had a bad reaction to the peanut and was rushed to the 
hospital. ‘They performed various tests and I got diagnosed with peanut allergy,’ says 
Wendy. From that moment on the foods which I could not, or could eat were at the 
centre of attention. My mother could no longer prepare the meals that she used to 
because she could not be certain that there were no traces of peanut. This had impact 
on our whole family. Nowadays, I prepare most meals myself because then I can be sure 
that there are no peanuts in it. Sometimes that is difficult because it prevents me from 
spontaneously going out to eat with friends. That is because everyone always has to 
take my peanut allergy into consideration. It is difficult because not everyone does that. 
‘Sometimes I go to birthday parties where peanuts are being served. This means that I 
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have to be extra carful to avoid getting in contact with the peanuts because I may get an 
allergic reaction from very small amounts of peanut. I always ask them to remove the 
peanuts. Many people will serve something else instead, but others cannot image that 
peanuts make me will, or that I may die from them’.  
It can be very difficult to avoid peanuts. Her boy friend kissed her after eating peanut 
M&Ms. ‘Obviously, he was terrified. He knew I am allergic, but had not realised that a 
kiss can be dangerous for me.’ Everyone in her life becomes affected by my allergy. ‘I 
can never just enjoy food,’ Wendy explains, ‘I always have to check the ingredients to 
see if the food is safe for me to eat, every day, every meal.’ 
 67 
Novel food information for non-food allergic consumers, information scenario and 
for food allergic consumers 
 
It is possible to produce hypoallergenic foods. This means that these foods contain less 
of the substances that can cause an allergic reaction for people that are allergic for this 
substance. There are several ways in which foods can contain less allergens.  
 
In this questionnaire we mention three different types of these novel foods: 
• Natural novel foods: These are foods that are less allergenic because there are 
natural differences between different varieties of the same sort. 
• Technological novel foods: these are foods that we know already but can be 
named novel, because a new processing technique or production method has 
been used, like extreme high pressure or high temperatures. 
• Genetic modified novel foods: these are foods from which the allergens have 
been removed. Nothing has been added to these foods. 
 
Benefits of hypoallergenic foods 
 
The most important benefit of all these foods are that they do not cause allergic 
reactions, or maybe some mild complaints in the worst case. Because of this, allergic 
people do not have to be extremely alert to products to which they are allergic. This 
facilitates allergen avoidance.  
 
They do not have to worry constantly that they might have a (deadly) allergic reaction 
when they eat something. Because of these novel foods, there will be more products for 
consumers to choose from. 
 
Which methods are used to make foods hypoallergenic, does not matter. The benefits 
mentioned above can be reached by using natural novel products, but also by genetically 
modifying foods or by applying a new technological treatment, like a very high 
temperature or high pressure. 
 68 
Annex C: Neutral information for non-food allergic consumers 
 
Food 
With “food” we mean all organic substances that are needed by a human being. 
With these substances, the body can produce energy to facilitate all processes in the 
cells. Which substances can or cannot serve the human being has been proved 
throughout the years through natural selection. Through trial and error is determined 
what is poisonous and therefore destructive is for the organism. This knowledge is 
transmitted in word or in writing. 
Food for humans has been developed for a long time. First we ate our food 
mainly raw, but soon it became the habit to prepare our food. The food became more 
tasteful but also easier to digest. Our food has, from the fifties in the twentieth century, 
changed enormously. With the development and availability of food science, our food 
changed and improved. Conservation techniques make it possible to preserve food for a 
long time. In the sixties of the twenties century, a contra-movement arose, consisting of 
people that became vegan or vegetarian, and of people that started to make and sell 
biological food, that was grown in the ecological agriculture. 
 
Healthy food 
Every food consists of different nutrient in changing amounts. The highest change 
that the body receives enough of all nutrients is by eating varied food. The basic concept 
of healthy food that was recommended by the “Voedingscentrum”, makes sure enough 
nutrients are available for the body. These guidelines direct of a large amount of read, 
potatoes, rice, pasta, legumes, vegetables and fruits and two times a week fish. This is 
completed with dairy and meat, eggs or meat substitute and margarine or bake and 
frying products. Sufficient fluids are also essential. 
Many people eat too much and in a wrong way. Healthy food contributes to a 
healthy life. It supplies nutrients that are necessary to keep the body healthy. Healthy 
food in combination with sufficient exercise is the base for a healthy weight and 
diminishes the risk on chronical diseases, like cardiac diseases, diabetic and several 
forms of cancer. Foods like sauces, snacks, cookies, candy and pastry are not included 
in a balanced diet. These products are providing too many calories. Furthermore they 
are less important in supplying nutrients. Healthy food also means: do not eat too much 
out side the balanced diet guidelines. Choose consciously for healthy food and enjoy it! 
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Novel foods 
The last few years a lot of new foods have entered the supermarkets. In the 
questionnaire (of this research, which you will receive shortly) we will mention three 
types of novel foods. 
• Natural novel foods: which are foods that are eaten around the world but are just 
recently introduced in the Dutch supermarkets. 
• Technological novel foods: these are foods that we have known for some time, 
but can be named new, because a new processing technique or production 
method has been used, like extreme high pressure or high temperatures. 
• Genetically modified novel foods: these are foods that have been improved by 
changing their genetic (or hereditary) characteristics. 
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Chapter 5 
Novel foods and allergy: regulations and risk-benefit 
assessment 
 
  Submitted for publication 
 
 
Abstract 
Hypoallergenic novel foods may have benefits for food allergic consumers. 
However, other novel foods may exacerbate the problems associated with food allergy. 
This chapter reviews the existing legislation associated with the introduction of novel 
foods and assesses the efficacy of such legislation with respect to allergy risks and 
benefits. Various regulations are in place to protect consumer health. These regulations 
require novel food safety to be assessed before they can enter the market, but do not 
specify how this assessment, which includes allergenicity should be performed. It is 
concluded that including a benefit assessment in the novel food legislation, may be 
beneficial. 
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5.1 Introduction 
There has been considerable societal discussion regarding the potential 
advantages associated with the introduction of novel foods and ingredients into the food 
chain, in response to societal recognition of the potential benefits as associated with 
these products. Proposed benefits may relate to improvements in public health, 
diversification of nutritional intake, or improved food security or quality (Putten et al., 
2006). The designation “novel foods” as used in the current discussion pertains to foods 
or food ingredients with no history of widespread and safe consumption. The novelty of a 
food can be the result of: (1) genetic modification (GM) of the food itself, or its production 
using genetically modified (GM) organisms, (2) the application of novel processing 
techniques, such as new types of heat processing, non-thermal preservation methods 
and the application of new processes catalysed by enzymes, or (3) the food in question 
having no prior history of consumption in general, or in a specific region or country, such 
as for “natural” non-GM foods (Putten et al., 2006). One rationale for developing novel 
foods is to reduce the incidence of food allergy by eliminating or substituting proteins 
which provoke allergic responses. However, it is important to note that other novel foods 
may exacerbate the prevalence of food allergy as novel potentially allergenic proteins 
are introduced into the food chain, or to the diets of individuals hitherto unexposed to 
them. 
Food allergy, a hypersensitivity reaction initiated by immunologic mechanisms to 
normally harmless food components, affects between 5 to 8% of children and 1 to 2% of 
adults (Rona et al., 2007). In the discussion that follows, food allergy is understood to 
refer to IgE mediated reactions of the human immune system to food. The development 
of hypoallergenic novel foods and ingredients may be utilised to develop a food allergy 
management strategy that potentially improves the quality of life of food allergic 
consumers. However, it is also important to acknowledge that the introduction of novel 
foods and ingredients has the potential to introduce allergenic proteins into the food 
chain. For example, at the time of writing, concerns exist about the potential of novel 
foods to introduce new allergens into the foods chain (Putten et al., 2006). In addition, 
there is little information available regarding consumer attitudes independent towards 
novel hypoallergenic foods, independent of whether consumers suffer from a food allergy 
(Schenk et al., 2008). Thus, on one hand novel hypoallergenic foods may improve the 
quality of life of food allergic consumers by reducing dietary restrictions. On the other 
hand, novel foods have potential to exacerbate the incidence of food allergy. In both 
cases, it is important to examine how existing regulatory frameworks designed to 
optimise consumer protection deal with the case of novel foods and food allergy. For this 
 73 
purpose it is interesting to compare these frameworks as being operational in different 
countries worldwide. 
The aim of this chapter is to review the existing legislation associated with the 
introduction of different types of novel foods, to assess the efficacy of such legislation 
with respect to risks (and benefits) of novel foods associated with food allergy, and to 
identify where additional information may be required to protect food allergic consumers. 
The focus of the review will be the European legislation. This will be compared to a 
select number of legislations with well-established regulations pertaining to novel foods, 
i.e. Canada, the USA, and Australia-New Zealand. Existing regulatory frameworks have 
been developed to protect human health in relation to novel food safety. These 
frameworks do not indicate how novel food allergenicity should be assessed. Therefore, 
the safety assessment methods currently available for the different types of novel foods 
are presented. It is also important to note that many emerging food risk governance 
models posit that an assessment of both the risks as well as the benefits associated with 
a food issue are required, and furthermore, to broaden risk and benefit assessments 
towards the impacts on health and other socio-economic issues (Wentholt et al., in 
press). Therefore an overview of the potential benefits of novel foods for food allergic 
consumers will be discussed. 
 
5.2 Novel food legislation 
Various legislations have regulations in place that require novel foods be legally 
approved before entering the market. Such regulations usually also require that these 
novel foods be assessed for their safety. In an increasingly globalised and complex food 
system, it is important to consider how different legislatures consider specific food safety 
issues, as lack of regulatory harmonisation may be problematic if foods and food 
ingredients are exported between different regions of the world (Marvin et al., 2009)). 
This applies to novel foods and ingredients entering the food chain, whether as products 
which have the potential to sensitise new populations hitherto unexposed to the 
problematic proteins, or who may differentially respond to novel hypoallergenic foods 
assessed in different regulatory regimes. 
 
5.2.1 European Union 
The EU defines novel foods as “foods and food ingredients that have not been 
used for human consumption to a significant degree within the Community” (European 
Commission, 2008a). To enable a novel food to be placed on the market in the European 
Union, Regulation (EC) 258/97 of the European Parliament and the Council applies 
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(European Parliament and European Parliament and the Council, 1997). At the time of 
writing, a new proposal for amendment of Regulation (EC) 258/97 is being discussed at 
the EU political level. As no decision has been taken yet to the adoption of the proposed 
amendments, it is not possible to discuss these16. When Regulation (EC) 258/97 went 
into force, it applied to novel foods and food ingredients that have not been available on 
the EU market to a significant degree before May 1997. The scope of Regulation (EC) 
258/97 initially also included GM foods and ingredients. However, since 2005, GM foods 
and ingredients have to be assessed for their safety, and to be approved for their market 
introduction under Regulation (EC) 1829/2003 (European Parliament and the Council, 
2003b). 
Before being placed on the EU market, the novel foods and food ingredients 
referred to in Regulation (EC) 258/97 must undergo a safety assessment, as a result of 
which an authorisation decision may be taken by the European Commission. This safety 
assessment focuses on the systematic and objective evaluation of all available 
information about the novel food. During the assessment procedure, the competent 
authority of a Member State that receives an application must make an initial 
assessment and determine whether or not an additional assessment is required. If 
neither the Commission, nor the Member State raises an objection, and if no additional 
assessment is required, the Member State informs the applicant that he may place the 
product on the market. In other cases, a procedure is followed in which the European 
Commission seeks scientific advice from the European Food Safety Authority, (EFSA) 
based upon which the European Commission drafts a decision. This draft decision is 
subsequently submitted to the Standing Committee on the Food Chain and Animal 
Health, and, depending on the outcomes of that, may be submitted to the Council of 
Ministers, before an official decision can be taken by the Commission (SCADPlus, 2008). 
The information needed when a novel food application is made, depends on the 
characterisations of the type of novel food, and is described in Commission 
recommendation 97/618/EC (European Parliament and European Parliament and the 
Council, 1997). Specifically, information is required in thirteen categories, ranging from a 
specification of the novel foods and the effect of the production process on the novel 
foods to projections of anticipated intakes, which are needed to evaluate the dietary and 
nutritional consequences of the novel food. Toxicological information, which includes  
                                               
16
 The proposal for amendment of Regulation 258/97 intents to exclude foods derived from cloned 
animals and their offspring from the scope of the regulation, as well as to have foods produced by 
nanotechnology to undergo a specific risk assessment before being approved for use. 
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Table 5.1 Evaluated novel foods in the EU (EC, 2008a) 
Description of 
Food or Food Ingredient 
European 
Commission 
decision 
Additional 
information 
Stevia rebaudiana (plant and dried leaves) Refused Sweetener 
Phospholipids from egg yolk Authorised Novel processing 
technique 
Yellow fat spreads with added phytosterol-esters Authorised Lower blood cholesterol 
Fruit preparations pasteurised using a high pressure 
treatment process 
Authorised Novel processing 
technique 
Nangai nut Refused novel food 
Bacterial dextran Authorised Polysaccharide for use 
in bakery products 
Salatrim Authorised Fat replacer 
Tahitian Noni Juice Authorised Ingredient in fruit juice 
mixtures 
Trehalose Authorised Sweetener 
REDUCOL™ Authorised Lowers blood 
cholesterol 
Plant sterol enriched bakery products, grain based 
snack products and gum Arabic pastills 
Authorised Improves blood 
cholesterol 
Coagulated potato protein and hydrolysates thereof Authorised Novel food ingredient 
DHA-rich Oil Authorised Novel food ingredient 
with energy reduction 
effect 
Phytosterol enriched fat ingredient – Diminicol Authorised Lower blood cholesterol 
Multibene® - Ingredient Authorised Lower blood cholesterol 
Plant Sterols and Sterol Esters Authorised Lower blood cholesterol 
Rapeseed oil high in unsaponifiable matter Authorised Novel food ingredient 
Maize germ oil high in unsaponifiable matter Authorised Novel food ingredient 
ENOVA™-oil Diacylglycerol Oil (DAG oil) Authorised Replace conventional 
oils 
Phytosterol-esters: Use in a range of products Authorised Lower blood cholesterol 
Iodine enriched wild-type eggs Refused Novel food 
(consumption egg) 
Betaine Refused Use in drinks, cereal 
products, confectionary 
and dairy products 
Deer horn powder Refused Dietary supplement 
Isomaltulose Authorised Sweetener 
Lycopene from Blakeslea trispora Authorised novel food ingredient 
Allanblackia seed oil for use in yellow fat spread and 
cream based spreads 
Authorised Ingredient in yellow fat 
and cream based 
spreads 
α-Cyclodextrin Authorised Added as dietary fiber 
Diminicol® rice drink with added phytosterols Authorised Extended use of 
phytosterol ingredient 
diminicol 
Tagatose Authorised Sweetener 
MultOils (oil containing a diacylglycerol-rich fat 
component and a free phytosterol esters component) 
Authorised Lower blood cholesterol 
Baobab (Adansonia digitata) dried fruit pulp Authorised Use in fruit bars and 
smoothies 
Refined Echium oil (Echium plantagineum) Authorised Novel food ingredient 
 
information about the potential allergenicity, is also required (European Parliament and 
the Council, 1997). These recommendations only indicate what type of information 
should be presented. It does not recommend how this information should be gathered. 
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This may relate to the fact that allergenicity assessments need to be carried out on a 
case-by-case basis (Taylor and Hefle, 2001). 
 
At the time of writing, a total of 91 novel foods have been submitted for 
authorisation in the EU (European Commission, 2008b). Table 5.1 gives an overview of 
novel foods that have received an EU decision about their authorisation under 
Regulation (EC) 258/97 (European Commission, 2008a). GM novel foods that are only 
novel because of genetic modification are not listed in this table. This is because not all 
GM novel foods which have been authorised in the EU have been evaluated under 
Regulation (EC) 258/97. Some of the applications have been withdrawn, and for others 
the assessment procedure is still pending at time of writing. Most novel food applications 
that have been made in the EU are products that can be used as an ingredient for food 
products. The European Commission has made a decision on 37 novel foods. Five of 
these novel foods have been refused because their compliance with the criteria laid 
down in article 3 (1) of Regulation (EC) 258/97 could not be demonstrated. This article 
states that “novel foods and food ingredients must not present a danger to the consumer; 
mislead the consumer or differ from foods or food ingredients which they are intended to 
replace to such an extent that their normal consumption would be nutritionally 
disadvantageous for the consumer”. In the case of Stevia rebaudiana, a novel food to be 
used as a sweetener (SCF, 1999) and of nangai nuts, a novel introduction to the 
European market from the pacific region (SCF, 2000), the scientific opinions were based 
on the lack of essential data, including, but not confined to, data on allergenicity, pre-
empting a conclusion on the safety of these products. For betaine, a food additive 
claimed to prevent cardiovascular disease, the scientific opinion is explicit about the fact 
that no clarification has been provided for test-substance related effects in an animal 
toxicity study, and therefore no safe levels could be established (EFSA, 2008). For 
iodine-enriched eggs, which result from the combination of the Columbus egg, rich in 
polyunsaturated fats, and the Japanese Hikari egg, which is rich in Iodine, the authorities 
of the EU member state (Belgium) where the application had been filed raised objections 
based on the possibility of the exceedance of the safe upper level of iodine intake by 
consumers, about which the other members did not express disagreement. Thirty-two 
novel foods have been authorised for marketing in the EU because their safety has been 
sufficiently demonstrated and because they do meet the criteria as laid out in Regulation 
(EC) 258/97. The European Commission’s Community Register of GM organisms with 
authorised uses in food and feed currently contains 26 GMOs, including six GM cotton, 
12 GM maize, biomasses from two GM micro-organisms, three GM oilseed rape, two GM 
soybeans and one GM sugar beet. These have several authorised uses each, for 
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example the BT11 maize that is authorised to be used for foods and food ingredients, 
food additives, feed, and for other products (European Commission, 2008c). The 
dossiers on the novel foods as summarised in the published safety assessments do 
contain information in the relevant categories from Commission recommendation 
97/618/EC. However, little information can be found on the allergenicity assessment of 
the non-GM novel foods in the published approvals and summaries of the dossier 
evaluations, given that the original dossiers are usually confidential and not freely 
accessible. This contrasts with the evaluations of GM foods, for which the allergenicity 
assessment is a common feature. In the summaries of the evaluations of most non-GM 
novel foods dossiers, allergenicity assessment is not mentioned at all and in the 
summaries of dossiers where attention is paid to the potential allergenicity of the novel 
food, the assessment is limited to remarks that there is no reason for concern, or that 
there are no indications of allergenicity. How this conclusion was reached is not 
specified, however. For only a few novel foods such as Ice Structuring Protein, which has 
benefits both in terms of nutritional and organoleptic profile, and greater temperature 
stability (Crevel et al., 2007) the scientific opinion’s summary of the dossier provides 
more information about the allergenicity assessment such as amino acid sequence 
comparison to known allergens, in vitro breakdown by pepsin, IgE binding screening, 
and skin prick tests (CBG-MEB, 2008). For some novel foods, scientific studies can be 
found that investigate the (potential) allergenicity. Crevel et al. (2007) report a study with 
human subjects who consumed ice structuring protein for several weeks and remained in 
good health, and who developed no IgE antibodies, affirming previous conclusions that 
these ice structuring proteins are unlikely to have allergenic potential (Crevel et al., 
2007). In addition, the EFSA Panel on Dietetic Products, Nutrition, and Allergies (NDA 
Panel) describes a sensitisation study in guinea pigs, which received repeated 
subcutaneous injections (i.e. beneath their skin) of extracts of leaves of the noni plant 
(Morinda citrifolia), which can be used as an ingredient for fruit juices, but which did not 
exhibit signs of allergic reactions after oral challenge with the same extracts (EFSA, 
2008). This is similar to a sensitisation test in guinea pigs that has been performed with 
the juice of noni fruits (SCF, 2002). Some of the opinions on these applications also 
mention potential health benefits. An example is provided by phytosterols, which 
potentially inhibit the absorption of cholesterol (CBG-MEB, 2008). On the other hand, the 
assessment of chia seeds, rich in omega-3 fatty acids and a potential source of 
antioxidants, as a novel food by EFSA’s NDA Panel revealed cross-reactivity with peanut 
in serum binding and with sesame in skin prick testing when chia was tested (EFSA, 
2008). 
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In addition to legislation regarding the marketing of novel foods, the EU also has 
legislation regarding the labelling of allergens. Novel foods are subjected to the general 
labelling requirements (Directive 2000/13/EC), but they may require specific additional 
information. Directive 2003/89/EC amends the general labelling directive and states that 
in order to protect food allergic consumers, the use of certain ingredients should be 
specified on the product label. These ingredients are cereals containing gluten, 
crustaceans, eggs, fish, peanuts, soybeans, milk and dairy products, nuts, sesame 
seeds, and sulphite at concentrations of at least 10 mg/ (European Parliament and the 
Council, 2003a). It should be noted that this labelling directive applies to foods that are 
available in the EU. This directive will only apply to novel foods, once they have been 
approved in the EU under regulation 258/97. 
 
5.2.2 Australia- New Zealand, Canada and USA: differences and similarities with 
EU legislation 
 
Figure 5.1 gives an overview of the novel foods safety assessment procedures in 
the EU, in comparison to procedures in Canada, Australia-New Zealand, and the USA.  
 
Figure 5.1 Legal categories of novel foods and processes in the food legislations of EU, Canada, 
Australia-New Zealand and USA. 
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The Canadian legislation describes novel foods as foods that result from a process not 
previously used for food, as products that do not have a history of safe use as a food, or 
as foods that have been modified by genetic modification also known as genetically 
modified foods, GM foods, genetically engineered foods, or biotechnology derived foods 
(Health Canada, 2008a). In practice, this means that most of the novel foods assessed 
are GM or derived from certain mutation-bred crops. The Canadian approvals also 
pertain to a number of novel processes, e.g. UV-disinfection of apple juice and high-
pressure pasteurisation of meat (Health Canada, 2008b). Allergenicity assessment is 
included as part of the approval process. How the potential allergenicity should be 
assessed is specified in neither Canadian legislation nor European legislation. 
The Food Standards Australia New Zealand (FSANZ) agency describes novel 
foods as non- traditional foods with characteristics that require an assessment of public 
health and safety considerations (Food Standards Australia New Zealand, 2008b). A 
non-traditional food is a food that has no history of human consumption in Australia or 
New Zealand. This also includes substances derived from a food, that have not been 
consumed other than as a component of the food, and substances that come from a 
source without history of consumption in Australia or New Zealand. Key areas 
influencing the interpretation of the term ‘history of human consumption’ are the length of 
use; the extent of use; the quantity (level of intake) of use; and the purpose or context of 
use (Food Standards Australia New Zealand, 2008a). As is the case in Canada and the 
EU, allergenicity assessment is included as part of the approval process, but regulations 
neither specify how this allergenicity assessment should be performed. The USA does 
not specifically distinguish novel foods as a class of products. Instead, a substance that 
will be added to food is subject to premarket approval by FDA unless its use is generally 
recognized as safe (GRAS) by qualified experts, or if it is a prior sanctioned substance 
that the FDA or USDA determined safe for use in food before 1958 (International Food 
Information Council US Food and Drug Administration, 2008). The GRAS procedure is a 
notification procedure. A product is GRAS through (1) scientific procedures, which may 
be corroborated by unpublished studies and other data and information, or (2) 
experience based on common use in foods requires a substantial history of consumption 
for food use by a significant number of consumers (International Food Information 
Council US Food and Drug Administration, 2008). If a substance is not generally 
recognised as safe or a prior sanctioned substance, it is considered a food additive and 
must be subject to a mandatory safety assessment by FDA, which includes 
comprehensive toxicological testing, genetic toxicity, acute oral toxicity, short term 
toxicity, (sub)chronic toxicity, and reproduction and developmental toxicity (International 
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Food Information Council US Food and Drug Administration, 2007). Potential 
allergenicity is not specifically mentioned in the FDA Redbook, which applies to all food 
additives. The potential allergenicity of transgenic proteins has been considered in their 
safety assessment (International Food Information Council US Food and Drug 
Administration, 2008). It should be noted that the definition of a food additive may 
diverge between the American and other legislations. In the EU, for example, food 
additives are defined by Directive 89/107/EEC as food substances that are added to 
foods in limited quantities and that serve a technological purpose, examples being 
colorants and sweeteners. As for the other legislative frameworks considered, 
allergenicity assessment is included as part of the approval process, but how this should 
be done is not specified. 
When comparing the various novel food regulations, it is relevant to note that that 
Canada regulates GM foods as novel foods, where in the EU this has not been the case 
since 2005 with the implementation of a specific regulation pertaining to GM food and 
feed, i.e. 1829/2003, amending the Novel Food Regulation (EC) 258/97 (European 
Parliament and the Council, 2003b). The Food Standard Australia New-Zealand 
(FSANZ), as is the case in the EU, does not classify GM foods as novel foods. Canadian 
legislation refers to a lack of a history of safe use of the food for the food to be novel, 
whereas EU legislation only refers to a history of use. The FSANZ does not use ‘history 
of safe use’ as a criterion to define a novel food. Instead, the FSANZ only refers to a 
‘history of use’ in Australia of New Zealand when describing non traditional foods. 
Appropriate regulatory agencies in each country assess the safety of all novel foods 
proposed for sale in the particular countries. When comparing the safety assessment 
procedures, caution must be taken because definitions of novel foods in these countries 
differ and, as a consequence, the assessment procedures also differ, in such a way that 
they cannot be compared directly. All countries do include allergenicity in the safety 
assessment. However, no comparisons are possible since the allergenicity assessment 
procedures are not described. It is important to note that although the various novel food 
legislations have some similarities, authorisation of a novel food in one country does not 
imply that the novel food can be imported to another country without further safety 
assessment. 
5.3 Novel Food safety assessment 
Before the safety of novel foods can be discussed, two points need to be clarified. 
The first point is that sensitisation to potential allergens is required before allergenic 
reactions will take place upon re-exposure to these same allergens. Food products that 
contain potentially sensitising novel proteins could change the exposure of the 
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population to these proteins, thereby potentially giving rise to the development of new 
allergies. For the allergenicity assessment two aspects are important: (1) de-novo 
sensitisation by completely new allergens and (2) cross-reactivity with allergens that are 
similar to the ones to which the food allergic consumer is already sensitised. De-novo 
sensitisation by completely new allergens is more difficult to predict than cross-reactivity. 
Therefore, this chapter focuses on potential cross-reactions of novel foods rather than on 
sensitisation. Given that, by definition, novel foods have no history of safe use in the EU, 
safety assessment is necessary to assure human health. The second point is that where 
possible, safety assessment of foods uses traditional foods and ingredients as reference 
points and the assessment process focuses on the differences between these and the 
novel foods and ingredients under assessment (Howlett et al., 2003). An example of this 
is the evaluation of substantial equivalence of oil derived from two distinct GM cotton 
lines, Insect Protected line 531 and Roundup Ready line 1445. It was agreed that 
processed oils derived from these lines were equivalent, in composition, to oils from 
conventional cottonseed varieties (ACNFP, 2008). 
The methods available to test novel foods allergenicity vary for and depend on 
the type of novel food under assessment. Table 2 provides an overview of the various 
(complementary) assessment methods that are available to assess the safety of the 
different types of novel foods. This Discussion of the available methods to assess 
allergenicity of GM novel foods for which the available methods are documented is 
provided (Codex Alimentarius Commission, 2002; FAO/WHO, 2001). This is followed by 
a discussion of possible methods to determine allergenicity of non-GM technological 
novel foods, for which at the moment fewer methods are available. This paragraph ends 
with a discussion of available allergy testing methods for the other novel foods. 
 
Table 5.2 Assessment strategies available for different types of novel foods. 
 GM Non GM tech Non Native 
Source/ Phylogenetic relationship ●  ● 
Amino acid sequence ●   
Pepsin resistance ● ● ● 
IgE binding ● ● ● 
Level of expression novel protein ●   
Animal models (when available and 
validated) 
● ● ● 
Previous human exposure (to novel 
food) 
  ● 
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5.3.1 Safety of GM novel foods 
The allergenicity assessment of GM products, (usually common food crops into 
which a foreign gene coding for a novel protein has been introduced) considers both the 
novel protein and the product that receives the novel protein. A specific concern for food 
safety in the case of GM novel foods is the expression of novel allergenic proteins in 
transgenic crops. No single test exists that is fully predictive of the potential allergenicity 
of any specific novel protein (Taylor, 2006) and therefore the assessment of potential 
allergenicity should combine various criteria, according to the “weight of evidence 
approach” recommended by Codex Alimentarius, including the source of the protein, 
amino acid sequence homology to known allergens, pepsin resistance and specific 
serum screening (Codex Alimentarius Commission, 2002). 
One of the criteria considered in the assessment of potential allergenicity of GM 
novel foods is the gene source. If, for example, the gene has been obtained from an 
allergenic source, i.e. an organism known to cause allergic reactions in allergic 
consumers, then the potential allergenicity of the gene product in these consumers has 
to be considered. Moreover, if the protein encoded by the specific gene, i.e. the gene 
product has already been established as an allergen, then it has to be verified whether it 
has maintained its allergenic properties in the transgenic plant (Stewart et al., 2000). An 
example of the product of a gene derived from an allergenic source is the Brazil nut’s 2S 
albumin, an allergenic protein that showed reactivity in Brazil nut allergic consumers after 
its transfer to an experimental GM soybean (Nordlee, 1996). If the gene source has an 
unknown history of allergenicity this still requires further investigation on whether it may 
be allergenic in a transgenic plant according to various criteria described below. In 
addition, also the history of allergenicity of the recipient organism of genetic modification 
is considered with regard to potential changes in intrinsic allergens caused by the 
genetic modification.  
Amino acid sequence comparison may be a tool to estimate whether a novel 
protein has allergenic potential. IgE cross-reactivity between the novel protein and a 
known allergen should be considered a possibility if there is more than 35% identity in a 
segment of 80 or more amino acids, or if both proteins share a segment of identical 
contiguous amino acids (Codex Alimentarius Commission, 2002; FAO/WHO, 2001). If 
there is no sequence homology, this indicates that the novel protein is not similar to 
known allergens and less likely to be cross-reactive to known allergens. A positive 
sequence homology result indicates that the protein is potentially cross-reactive with the 
known allergens. If the novel protein’s similarity to allergens is considered further, it 
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should be assessed using serum from individuals sensitised to the identified allergenic 
source (Codex Alimentarius Commission, 2002). Orruño and Morgan (2006) note that 
sequence homology and structural similarity to known allergens are not sufficient to 
predict cross-reactivity involving conformational epitopes consisting of a discontinuous 
amino acid sequence along a folded protein (Orruño and Morgan, 2006). According to 
these authors, more information is needed to exactly pinpoint epitopes. They do not 
explain their assumption as to why it is not possible to predict potential cross-reactivity of 
conformational epitopes. However, Aalberse and Stadler (2006) claim that allergenic 
potential can be easily assessed by a combination of in silico homology searches with a 
50% cut-off in overall sequence alignment, and in vitro IgE antibody assays (Aalberse 
and Stadler, 2006). They claim that the major limitation of bioinformatics, i.e. the use of 
computer algorithms to investigate data on and predict the properties of biological 
molecules, is the number of allergens missing from the database, particularly minor 
allergens from airborne sources, such as pollen, insects and moulds. Aalberse and 
Stadler (2006) do acknowledge that by focussing on the primary sequence, post-
translational modification, which is a possible source of cross-reactivity is overlooked 
since these processes are not fully determined by only the DNA sequence. 
Since a number of food allergens are stable to digestion, the latter represents an 
important criterion to predict allergenicity. While not all stable proteins are allergens, for 
the purpose of allergenicity evaluation, digestible proteins are believed to have lower 
potential for systemic exposure of the intact protein (Taylor, 2006). This means that such 
proteins are less likely to sensitise and cross-react through the oral route and trigger 
allergic reactions upon subsequent oral exposure. Resistance to degradation by the 
stomach enzyme pepsin in in-vitro model tests indicates that further analysis should be 
conducted. A lack of resistance to pepsin per se does not exclude that the novel protein 
can be an allergen (WHO, 2003). 
For proteins that originate from a known allergenic source or that have sequence 
homology with a known allergen, testing in immunological assays should be performed 
where sera are available. If a novel protein from a known allergenic source has negative 
results in in vitro immunoassays, this protein should undergo additional testing such as 
skin prick tests. A positive result would indicate a potential allergen. For proteins from 
sources not known to be allergenic and which do not exhibit sequence homology to 
known allergens, targeted serum screening with sera from patients allergic to allergens 
that are broadly related to the source of the transgene may be considered (WHO, 2003). 
Very little information exists regarding threshold doses for sensitisation and cross-
reactions. According to Taylor (2006), however, the level of expression of the novel 
protein is another factor that should be considered in the safety assessment of GM novel 
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foods. Foods produced through GM are less likely to become allergenic if the novel 
proteins are present in low concentrations, especially with regard to the expression in the 
edible portion of the modified plant. 
It should be noted that the allergenicity assessment strategy for transgenic 
proteins cannot be applied to novel foods in which a gene has been down regulated, 
thereby preventing the presence of a potential allergen in the product. When such a 
hypoallergenic novel food is developed, the safety assessment should involve the same 
testing procedures, and in addition the reduced allergy impact of this allergen should be 
assessed. 
 
5.3.2 Safety of non-GM technological novel foods 
During food processing, allergenicity can be altered by various procedures such 
as storage time, preparation techniques, heating, prolonged washing and interactions 
with other food components. As a result, the allergenic potential may be unaffected, 
decreased or even increased. Alterations in stability caused by processing may alter the 
resistance to digestion and the nature of the interaction with the immune system. 
Allergenicity can also be increased when new epitopes are exposed at the surface of the 
protein or formed by chemical reactions such as the Maillard reaction between 
carbohydrates and proteins while it can be reduced when former conformational epitopes 
are lost. An example of the exposure of a new epitope is the protein Beta-lactoglobulin 
from cow milk, which has a linear epitope buried within its structure. This linear epitope 
becomes exposed when the proteins structure changes through denaturation (Liu et al., 
2007). Alterations in allergenicity due to the exposure of new epitopes cannot be 
detected using amino acid sequence comparisons, which is an important assessment 
step for GM novel foods. For GM novel foods the novel protein was the most important 
subject of assessment. The proteins in the product are not known for all non-GM 
technological novel foods, which makes this strategy less useful. 
Validated animal models may offer the most direct approach for the determination 
of the intrinsic sensitising potential of novel proteins in the future. Currently, however, no 
validated and widely accepted animal model is available (Orruño and Morgan, 2006). 
Food allergy follows exposure to food as it is normally eaten, and not following exposure 
to isolated proteins. It is important to note that the normal allergenicity of the protein may 
be influenced by the interaction with other components present in the food matrix, such 
as lipids and sugars and of wider aspects of structure and localisation (Orruño and 
Morgan, 2006). 
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For GM novel foods, the result of the safety assessment procedure is a 
conclusion as to the likelihood of the novel protein being an allergen. Since for the 
assessment of non-GM technological novel foods, less well described assessment 
methods are available, the outcome of this safety assessment contains more 
uncertainties. 
  
5.3.3 Safety of natural novel foods 
Kiwi is an example of a food that had an unknown history of allergenicity, but 
nonetheless manifested itself as allergenic (Lucas et al., 2005). In the case of kiwi, two 
issues are at stake, including cross-reactivity between the kiwi and known allergens, 
such as bananas and latex, and de-novo sensitisation for the kiwi itself. Whilst the cross-
reactivity of new proteins is assessed for GM foods following a weight of evidence 
approach, this approach will not always be feasible for each new protein within a novel 
food, such as kiwi. If a food is completely new and it is not feasible to follow a weight of 
evidence approach for all new proteins within a novel food, the currently available 
allergenicity tests will not be sufficient to identify a truly novel allergen (Dearman and 
Kimber, 2009). Animal models could provide insight in the potential allergenicity of the 
food. Although currently no validated and widely accepted animal model is available, this 
is the most direct approach for determining the intrinsic sensitising potential of novel 
foods (Orruño and Morgan, 2006). 
Gubesch et al (2008) designed an approach to screen novel foods for the 
presence of pan-allergens, IgE binding of food allergens and clinical relevance of IgE 
binding. Their conclusion is that this three-step approach seems to be applicable for 
allergenicity testing of natural novel foods (Gubesch et al., 2007). However, they do 
recognise that as long as no validated methods for assessing de novo sensitisation 
capacity are available the overall allergenic potential of novel foods is impossible to 
predict. If indications for cross-reactivity exist based on the allergenic history of the food 
or its phylogenetic relationship with other allergenic foods, it is recommended that the 
allergenicity assessment of foods and food proteins should include immunoglobulin E 
(IgE) from the sera of allergic patients using tests such as solid phase immunoassays 
(RAST, ELISA, EAST). When the identification of the allergenic components of a food 
material is required, SDS-Page followed by immunoblotting is generally applied. 
 
5.3.4 Novel food safety 
The end result of the assessment procedures is a conclusion as to the likelihood 
of the novel foods being an allergen. Depending on the type of novel food, and the 
 86 
available information about that novel food, the likelihood contains varying uncertainty. 
No safety or risk assessment procedure can lead to the guaranteed safety of novel foods 
for food allergic consumers, as the allergenicity of any given food or protein cannot be 
precluded completely, although the list of major food allergens is relatively limited 
(Breiteneder and Mills, 2005). For food allergic consumers who need to avoid all foods 
that contain the protein(s) to which they are allergic, this likelihood information is not 
sufficient (Putten et al., in press). Research about the labelling needs of food allergic 
consumers (Cornelisse-Vermaat et al., 2008b) shows that one of the problems faced by 
food allergic consumers is the uncertainty about whether a product contains allergens or 
not, especially when “may contain” labelling is used. Some food allergic consumers may 
even ignore the warnings on the label and try the food product to test whether an allergic 
reaction will occur and if it does never buy the product again (unpublished data). This 
phenomenon may not always be noticed by post-market monitoring. Consumers may 
respond similarly when informed about the remaining uncertainties of the current 
allergenicity assessment procedures. This calls for complete, clear and publicly available 
allergenicity risk assessment information that allows consumers to interpret the risk 
assessment results and make the risk management decisions that meet their individual 
needs best. Health professionals and patient organisations may play an important role in 
interpreting the allergenicity risk assessment information and helping food allergic 
consumers to decide whether a novel food is safe for them. Another factor adding to the 
uncertainty associated with the results of the safety assessment procedures are 
individual (genetic) differences in allergic responses. It has been frequently observed 
that different individuals react differently to different proteins within the same allergenic 
food (Orruño and Morgan, 2006). So-called major allergens provoke an allergic reaction 
in more than 50 percent of the patient population. In addition, minor allergens exist to 
which less of the population is allergic. When a major allergen is removed or mutated, 
some patients still may react to the minor allergens in a product, which makes it not safe 
for them to consume at all. 
The questions that remain relate to the level of risk which is acceptable, i.e. which 
level of safety is safe enough for food allergic consumers. The safety of a specific novel 
food depends on the allergy of an individual. Deciding when a food is safe for enough 
people, so it can be allowed on the market is a task for risk managers. The information 
that a safety assessment procedure provides is a first requirement to make further 
evaluations about whether novel foods may improve quality of life of food allergic 
consumers. 
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5.4 Potential benefits of novel foods for food allergic consumers 
Various novel food regulations aim to ensure consumer protection and require 
therefore risk assessment before novel foods can be marketed. At the present time, food 
risk management decisions are primarily based on risk assessment information, and 
allergy assessment does not differ in this regard (FAO/WHO 1998). Emerging food risk 
governance models are based on an assessment of both risks and benefits associated 
with a food issue, and, furthermore, that these risks and benefit assessment should be 
broadened to embrace not only health impact, but also other socio-economic and ethical 
impacts (Wentholt et al., in press). In the case of novel foods there are arguments to 
support the idea that this broader definition of impact assessment should be formally 
included in management decisions. Formal inclusion at the assessment stage would 
imply the introduction of novel methodological approaches to metricisation of risk and 
benefit so that both can formally be considered at the management stage. 
Food allergic consumers may profit from benefits of hypoallergenic novel foods 
through increased dietary variation and reduced restrictions on product selection and 
thereby reduction in the social limitations that food allergic consumers experience. Food 
allergy can have a profound impact on quality of life, not only because of the immediate 
clinical effects related to individual’s allergic condition, but also because of the alterations 
in daily life that have to be made to prevent the occurrence of symptoms and the 
influence on psychosocial functioning of the individual (Blok et al., 2007; Oude Elberink 
et al., 2002; Sicherer et al., 2001). Exposure to a food allergen can result in anaphylaxis, 
which may be severe enough to be life-threatening (Jackson, 2003; Sampson, 1999a). 
Other factors potentially influencing the quality of life of food allergic consumers include 
increased time spent shopping (Cornelisse-Vermaat et al., 2008b; Voordouw et al., 
2009) and increased costs to both the household and to the health services (Fox et al., 
accepted, subject to revision). 
Thus novel hypoallergenic novel foods have the potential to improve the quality of 
life of food allergic consumers, although one might assume the impact on quality of life 
experienced by the allergic consumer is contingent on the degree of severity of the 
reaction experienced and the level of certainty that it will be avoided by consuming the 
hypoallergenic novel food. Against this, there is also potential for novel foods to increase 
the prevalence of allergic responses, through the introduction of problematic proteins into 
the food chain. When novel foods are considered to be safe for food allergic consumers, 
this can become a benefit. However, the results of the safety assessment procedures 
regarding allergenicity are conclusions as to the likelihood of the novel foods being an 
allergen. This means that the conclusions regarding benefits are somewhat uncertain. 
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Another issue is that allergenicity is not a simple matter of deciding whether a novel food 
is allergenic. Depending on the allergenic content and the individual response of the food 
allergic consumer, one novel food may be more allergenic than another. The same 
principle applies to benefits. When a novel food is considered to be hypoallergenic, it 
means that it contains less allergen than the traditional variant of the food. A question 
arises as to what level of certainty regarding the hypoallergenicity of novel foods is 
required for novel foods to be used as allergy management strategy. No legal definition 
of hypoallergenic exists, although in clinical terms hypoallergenic formulas (infant milk) 
are defined as those that are tolerated by ≥90% of infants with documented cow’s milk 
allergy (Herz, 2008). In an ideal situation absolute certainty regarding the absence of 
potential for allergic reactions would be available. For most novel foods, this absolute 
certainty cannot be provided. Absolute certainty about the hypoallergenicity of the novel 
food or ingredient may not be required by all consumers. However, it is important to 
make information about the risk and benefit assessment available to food allergic 
consumers, allowing them to make their own risk management decision. How this 
information should be made available to consumers needs to be addressed in future 
research. Formal risk assessment procedures should also consider potential benefits. 
Regulations should take this into account as well and make the results of the risks (and 
benefit) assessments of novel foods publicly available. 
Currently, the risk assessment procedures do not include the potential severity of 
the allergic responses. This information is relevant for risk managers, especially when 
considering the potential benefits of novel foods. Foods that are not allergenic may have 
more benefits for people with a severe and life-threatening allergy than for people with a 
mild allergy, since the former are likely to experience more problems with the strict and 
necessary food avoidance. However, the increased severity of an allergic response may 
also be associated with an increased level of uncertainty regarding the hypoallergenic 
properties of the food or food ingredient (Voordouw et al., 2009). Including the potential 
severity of an allergic reaction to a novel food will probably entail clinical testing which 
may have its ethical and practical limitations. 
No summary of novel food applications in the European Union mentions benefits 
of the novel food regarding hypoallergenicity. It can be envisaged though that some of 
the experiments that may be carried out in-vitro or in-vivo with human or animal subjects 
to support health-claims can also provide additional, useful indications of any safety 
issues linked to the consumption of the novel food. It should be noted that such health 
claims are not assessed under regulation 258/97, but have to be assessed through a 
separate procedure, which falls outside the scope of this review. However, at the time of 
writing, no novel foods that have been legally authorised by the European Union could 
 89 
be identified as hypo-allergenic. However, among the novel foods that have been 
assessed in Canada are “delicious soybean” and “TUSC-1 wheat”, in which the levels of 
major allergenic proteins in have been reduced. However, the reported purpose of these 
modifications relate to organoleptic or technical properties. In addition to this, it might be 
possible that new hypoallergenic foods with benefits for food allergic consumers exist 
that are not listed as novel. Apparently, current authorisation applications within the EU 
have not been primarily developed for their reduced allergenicity. However, it is possible 
that new food products access the EU market without evaluation under Regulation (EC) 
258/97 because they are not considered novel according to EU directive 258/97. An 
example is the Santana apple, an apple cultivar that is the result from the crossing of the 
cultivars Elstar and Priscilla. The aim of this crossing was to combine the fruit quality of 
Elstar apples with the disease resistance of Priscilla (Maas and Berker, 2008). There is 
evidence that Santana apples are hypoallergenic, at least for some consumers (Kootstra 
et al., 2007). Other examples can be found in literature such as rice (Nakamura and 
Matsuda, 1996), soybean (Herman et al., 2003), apple (Gilissen et al., 2005), and 
peanuts (Dodo et al., 2005). However, this review was limited to novel foods and a 
review of other new foods is recommended for the future. It may be worthwhile to 
investigate how many other unusual but not novel foods exist that may be associated 
with hypoallergenic properties. 
 
5.5 Conclusions 
This chapter reviewed allergenicity legislation, assessment procedures, and 
potential benefits of novel foods to improve quality of life of food allergic consumers. 
Various regulations are in place to protect consumer health. These regulations require 
novel food safety to be assessed before they can enter the market. However, the current 
regulatory frameworks do not specify how these assessments should be performed. The 
EU recommends which information is needed for a novel food application, but besides 
from mentioning that allergenicity information is required, it is not specified how this 
allergenicity assessment should be performed. In Canada, the USA and Australia/ New 
Zealand allergenicity assessment is also part of the approval procedure, but how this 
assessment should be performed is not specified in the legislations. The may relate to 
the fact that the safety assessment methods available and best suited depend on the 
type of novel food under assessment. None of the safety assessment include benefits 
assessment. However, when a hypoallergenic novel food with benefits for food allergic 
consumers is being evaluated, it can be argued that information about the potential 
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benefits should be formally included in management decisions and therefore the 
assessment of benefits would be helpful. 
The end result of the assessment procedures is a conclusion as to the likelihood 
of the novel food having allergenic potential. This implies that for approved novel foods, 
some uncertainty remains regarding the allergenicity. How consumers respond to this 
uncertainty needs to be addressed in future research. 
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Chapter 6 
General discussion 
 
Food allergy is defined as a hypersensitivity reaction that involves the immune 
system (Patriarca et al., 2009). Food allergy affects 5-8% of children and 1-2% of adults, 
although about 20% of people report an adverse reaction to food, which makes it an 
important health issue (Rona et al., 2007). At the time of writing, the only reliable 
treatment of food allergy is strict avoidance of the problematic foods. Food allergy can 
have a profound impact on quality of life, not only because of the immediate clinical 
effects related to an individual’s allergic condition, but also because of the alterations in 
daily life that have to be made to prevent the occurrence of symptoms and the influence 
on psychosocial functioning of the individual (Blok et al., 2007; Oude Elberink et al., 
2002; Primeau et al., 2000; Sicherer et al., 2001). 
Hypoallergenic novel foods are of interest to the management of food allergies. 
Food allergic consumers may profit from the availability of hypoallergenic novel foods, 
and possibly also consumers who have an increased risks of developing food allergies. 
Besides the potential benefits of hypoallergenic novel foods, other novel foods may 
increase food allergy prevalence.  
The research presented in this thesis investigated whether novel foods can be 
used as part of an allergy management strategy. Before novel foods can be successfully 
used for this purpose, food allergic consumers need to accept these hypoallergenic 
novel foods. In addition, also non-food allergic consumers should accept novel foods to 
be available for consumption. 
 
6.1 Summary and conclusions 
In chapter 2 of this thesis, the issues around novel foods and food allergies at the 
start of this research were reviewed. The first issue emerging from the literature review 
concerns the prevalence of food allergy. Although an increasing food allergy prevalence 
is frequently mentioned in food allergy literature, there is no agreement regarding the 
prevalence. This lack of agreement may be due to the difficulty in diagnosing food 
allergy, or to the varying definitions of food allergy that are used. One distinction in food 
allergy that can be made is that between ‘true’ food allergy and perceived food allergy. 
‘True’ food allergy refers to a formal diagnosis of food allergy, whereas ‘perceived’ food 
allergy refers to the people’s belief that they personally exhibit the symptoms of a food 
 92 
allergy, independent of whether a health professional would diagnose them as food 
allergic. There is general agreement that food allergy prevalence is higher in children 
than in adults because of an increased predisposition if children to develop food allergy 
and by the tendency of children to develop immunologic tolerance as they get older 
(Sampson, 1999b). 
Food allergies can have a significant impact on the quality of life and economic 
functioning of people who suffer from them, as well as wider implications for society more 
generally. Direct costs of food allergy include medical costs, whereas indirect costs are 
linked to factors such as work and productivity (Gergen, 2001). The latter have a much 
greater effect on individuals and families because these costs reflect the functioning and 
quality of life of the individual and his family. It is important to realise that the impact of 
food allergy on daily lives of food allergic consumers is not only a direct result from the 
disease and its symptoms, but also from the treatment: avoidance of the problematic 
foods. Restriction or complete elimination diets and emergency management of allergic 
reactions are at the time of writing the only reliable therapy to treat food allergy. This has 
a negative impact on quality of life. 
Another important issue relates to both the risks and the benefits associated with 
the introduction of novel foods. One potential benefit of novel foods is that of 
hypoallergenicity, although there is the potential risk that new proteins are introduced 
into the human food chain together with the novel foods. Consumer acceptance of novel 
foods is contingent on technical risk estimates, and consumer perceptions of risks and 
benefits. An important finding from literature was the concept of risk conflict, which refers 
to the differences between the way that experts and non-experts evaluate risks (Slovic, 
1999). Technical risk assessments are often used by experts and regulators to 
determine acceptable safety levels (Taylor and Hefle, 2001), although consumer 
decision-making is, in part, based on broader, societally relevant factors of concern 
(Frewer et al., 2004). People may tolerate some level of risk if they also perceive direct 
benefit (Frewer et al., 2003b). Novel foods with reduced or absent allergenicity may be 
perceived as beneficial by food allergic consumers and therefore acceptable. For non-
food allergic consumers, the perceived risks may outweigh the benefits. Chapter 2 
concludes that hypoallergenic novel foods, despite some uncertainty regarding the 
(hypo)allergenic potential, may contribute to food allergy management, by aiding food 
allergen avoidance. 
Because of the different perceptions concerning risks among experts and 
consumers, chapter 3 looks at whether novel foods can be used as allergy management 
strategy from both a stakeholder and food allergic consumer perspective. Stakeholder 
opinions (collected using semi-structured interviews) regarding the acceptability of 
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hypoallergenic novel foods were assessed. The opinions of food allergic consumers 
were collected during three focus group discussions (one comprising of anaphylactic 
food allergic consumers, and two comprising of consumers with less severe food 
allergies). Optimising a food allergy management strategy that involves the application of 
(hypoallergenic) novel foods is contingent on both stakeholder and consumer 
acceptance of novel foods and associated production processes where relevant. 
Most stakeholders believed that novel foods can, in theory, contribute to a 
solution for the food allergy problems they described because the novel foods can be 
hypoallergenic, and therefore they may represent a safe alternative for food allergic 
consumers. Natural novel foods are only a good alternative when the products are 
proven safe, but initially stakeholders considered them more as a cause of consumer’s 
food allergy problems. The stakeholders also mentioned some potential problems when 
novel foods are introduced, such as consumers who develop allergies to the novel 
proteins in novel foods. They also stressed that novel foods can only be effective as food 
allergy management strategy if consumers are willing to buy them. Food allergic 
consumers would be in favour of hypoallergenic novel foods being developed and 
commercialised. However, they did express doubts regarding the reduced allergenicity of 
such novel foods. Consumers perceived that novel foods could only be used as allergy 
management strategy when all allergenic food ingredients are replaced across all food 
chains completely. An advantage of hypoallergenic novel foods according to the food 
allergic consumers is that these novel foods could prevent or delay the development of 
new allergies because they are exposed to reduced levels of allergens.  Both 
stakeholders and food allergic consumers expressed some enthusiasm for the 
introduction of truly hypoallergenic novel foods. Whilst the results suggest that 
hypoallergenic novel foods may be acceptable to food allergic consumers, consumers 
expressed the view that a ‘cure’ for food allergy is preferred over substituting existing 
foods with hypoallergenic alternatives. 
Chapter 4 identifies consumer attitudes towards novel foods and assesses the 
impact of information about food allergy and novel foods on non-food allergic consumer 
acceptance, and thus if food developers and policy makers should be encouraged to 
invest in low allergen novel foods. The results show that hypoallergenic novel food 
acceptance as allergy management is more acceptable to consumers who perceive high 
benefits and low or medium risks. Many food allergic consumers did not perceive the 
benefits of hypoallergenic novel foods to be high and were less accepting of 
hypoallergenic novel foods as allergy management strategy. Both food allergic 
consumers and non-food allergic consumer acceptance of novel foods was higher for 
natural novel foods compared to genetically modified novel foods. It is concluded that the 
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application of novel foods as an allergy management strategy is complicated by the fact 
that many of the consumers who are supposed to experience the benefits of these novel 
foods are less likely to accept the novel foods. 
Chapter 5 reviews the existing legislation associated with the introduction of novel 
foods and assesses the efficacy of such legislation with respect to allergy risks and 
benefits. Various regulations are in place to protect consumer health. These regulations 
require novel food safety to be assessed before they can enter the market. However, the 
current regulatory frameworks do not specify how these assessments should be 
performed. The EU recommends which information is needed for a novel food 
application, but besides from mentioning that allergenicity information is required, it is not 
specified how this allergenicity assessment should be performed. This may relate to the 
fact that the safety assessment methods available and best suited depend on the type of 
novel food under assessment. None of the safety assessments include benefits 
assessment. However, when a hypoallergenic novel food with benefits for food allergic 
consumers is being evaluated, it can be argued that information about the potential 
benefits should be formally included in management decisions and therefore the 
assessment of benefits would be helpful. It is concluded that including a benefit 
assessment in the novel food legislation, may increase acceptability. 
 
6.2 Novel foods as allergy management strategy 
 Food allergy is an important health issue. The results from both the consumer 
focus group discussions and the literature review make this clear. In particular the impact 
on quality of life of food allergic consumers is significant due to the consequences for 
their daily lives, such as affects meal preparation activities in the home, reduced social 
activities (for both parents and children), and anxiety and stress. The time and effort that 
it takes to provide a safe environment for food allergic children has potential to cause a 
significant impact on daily life. This calls for a food allergy management strategy that 
eases the burden on food allergic consumers. The research presented in this thesis 
focussed on the contribution that novel foods may make to such a food allergy 
management strategy. Figure 6.1 presents an overview of the main concepts in this 
thesis and how they relate to food allergy management. The following sections discuss 
how these concepts relate to food allergy management. 
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Figure 6.1 Important concepts of novel foods as part of a food allergy management strategy. 
 
Food allergy management 
Food allergy management consists of two strategies, which are related to the two 
phases of the development of food allergy. This first strategy aims at preventing the 
development of a food allergy, and desensitising food allergic consumers, once they 
have been sensitised. The second strategy aims at preventing the occurrence of food 
allergy symptoms. This can be achieved by allergen avoidance. Hypoallergenic novel 
foods may play a role in both food allergy management strategies. 
Some indications exist that treatment with a hypoallergenic fragment of cow’s 
milk may prevent the onset of sensitisation to cow milk (Herz, 2008). This implies that 
some hypoallergenic novel foods could contribute to inducing immunological tolerance. 
However, whether early introduction of potential allergens, in forms with reduced 
allergenic potential, such as hypoallergenic novel foods, is helpful remains to be proven 
(Skripak and Sampson, 2008). The application of novel foods as desensitisation therapy 
was not recognised by the stakeholders nor by the food allergic consumers in this 
research. They did recognise the (theoretical) possibility of hypoallergenic novel foods to 
facilitate allergen avoidance, although this possibility may be limited in practice. 
Obviously hypoallergenic novel foods need to be available to consumers to be able to 
have such effects. This is indicated by the arrow from ‘novel foods as allergy 
management strategy’ to ‘hypoallergenic novel foods availability’. 
During the research presented in this thesis, no hypoallergenic novel foods could 
be identified and therefore, strictly speaking, novel foods are not likely to be beneficial for 
food allergic consumers. This does not mean that no further efforts should be made to 
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develop novel foods since other (consumer) benefits could be present. Further, some 
hypoallergenic new foods may exist that fall outside the definition of novel foods as 
stated in EU legislation. An example of such a food is the Santana apple (Kootstra et al., 
2007), which is new food and marketed as hypoallergenic. It is difficult to systematically 
identify these new foods. Other examples of hypoallergenic foods are the “delicious 
soybean” and “TUSC-1 wheat”, which are approved in Canada under Canadian novel 
food legislation. The modifications of these foods aimed to improve organoleptic or 
technical properties, but these also resulted in reduced levels of major allergenic 
proteins. This indicates that there may be hypoallergenic new foods available that can be 
used as part of allergy management strategies, although these food may not be 
marketed as hypoallergenic. This shows that hypoallergenic novel food availability is also 
influenced by stakeholder attitudes, such as the food industry who may decide to market 
a product as hypoallergenic.  
Besides the introduction of hypoallergenic novel foods to facilitate allergen 
avoidance, other measures can be identified to be applicable in allergy management 
strategies, such as improved information provision to a food allergic individual about the 
specific food allergy and its management, better diagnostic techniques that provide food 
allergic individuals with information about which allergens to avoid, and improved 
allergen traceability and allergen labelling which allows food allergic consumers to 
effectively avoid allergens (Mills, 2007). 
 
Novel food safety and uncertainty 
(Hypoallergenic) novel foods have to be safe. Not only for consumers in general, 
but also for food allergic consumers. The safety is novel foods is addressed in novel food 
legislation. (In figure 6.1 this is indicated by the arrow from novel food regulations to 
novel food safety.) Novel food legislation requires novel food safety to be assessed 
before novel foods are allowed onto the market. Although novel food legislation 
recognises other types of novel foods besides genetically modified novel foods, it does 
not state how the safety of these novel foods should be assessed. The currently 
available assessment procedures are best suited to assess the safety of novel proteins. 
This means that the safety of genetically modified novel foods and novel proteins can be 
adequately assessed. It should be noted that the result of an allergenic safety 
assessment procedure is a conclusion as to the likelihood of a food being allergenic. 
This means that some uncertainty remains regarding the allergenic safety of the novel 
food. 
Novel food regulations also affect the availability of hypoallergenic novel foods. 
This is indicated in figure 6.1 by the arrow from ´novel food regulations´ to 
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´hypoallergenic novel food availability´. It is important to realise that any available 
hypoallergenic novel food can be considered as safe, (otherwise regulations would 
prevent the novel food from being allowed onto the market) but not every safe novel food 
is hypoallergenic. Hypoallergenicity refers to the elimination, or removal of the biological 
activity of allergens (Herz, 2008). This means that hypoallergenic novel foods contain 
less allergen, quantitatively or qualitatively, than non-hypoallergenic novel foods. The 
benefit of novel hypoallergenic foods is that they can be safer than conventional 
products. A product that is only reasonably safe is less likely to have such benefits. 
Dearman & Kimber (2009) report that the outcome of the risk assessment procedure will 
be a decision as to whether accept, reject, or label the particular novel food (Dearman 
and Kimber, 2009). In the case when hypoallergenic novel foods are to be applied as 
allergy management strategy, (precautionary) labelling of potentially allergenic products 
is not acceptable. For hypoallergenic novel foods as allergy management strategy to be 
acceptable to food allergic consumers it is necessary that food allergic consumers get as 
much certainty as possible about the remaining allergenicity of the novel food product. 
Considering that absolute certainty about hypoallergenicity is not possible this 
(un)certainty regarding the hypoallergenicity of novel foods needs to receive special 
attention in case novel foods are applied as part of allergy management. The relation 
between hypoallergenic novel food availability and consumer acceptance is presented in 
figure 6.1 by arrows through risk and benefit perceptions. These perceptions are also 
influence by the uncertainty about the (hypo)allergenicity of novel foods. 
Further, it is interesting to note that rational decision making may increase 
awareness of uncertainty by drawing attention to the lack of better data (Hu et al., 2005). 
When there is heightened sensitivity to risk as in the case of food allergic consumers, 
certain recommendations regarding novel food use as part of an allergy management 
strategy may thus increase the experience of uncertainty. This should be taken into 
account when communicating the potential benefits of novel foods to food allergic 
consumers and requires more research to determine the best communication strategy. 
Consumer concerns regarding allergenicity of novel foods focus on hidden 
allergens and less on cross-reactivity and de-novo sensitisation. It is the avoidance of 
allergens that concerns them. That is why the potential allergen content of novel foods is 
of particular importance to them. It is technically possible to test the newly introduced 
allergen content of all novel foods, although in the case of natural novel foods, for which 
not all proteins have been identified, this may be expensive. If most cross-reacting 
allergens have been identified, then the uncertainty regarding the presence of cross-
reacting allergens in novel foods becomes relatively small. Considering that cross-
reactivity is not a major concern to food allergic consumers, this means that novel foods 
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for which cross-reaction safety cannot be guaranteed could still be acceptable to food 
allergic consumers. 
 
Food allergic consumers 
The successful application of hypoallergenic novel foods depends on consumer 
acceptance of these novel foods (indicated with the arrow from ´consumer acceptance´ 
to ´novel foods as allergy management strategy´ in figure 6.1). Most food allergic 
consumers expressed some enthusiasm during the focus group discussions about the 
application of novel foods as allergy mitigation strategy. These results were not 
confirmed during the consumer acceptance study, presented in chapter 4, which showed 
low acceptance of hypoallergenic novel foods among food allergic consumers. A first 
reason for this lack of confirmation could be that the problems associated with food 
allergy, include more than those that can be influenced by hypoallergenic novel foods. 
For example, the most problematic aspect of food allergy is avoiding foods that may 
contain allergens. It is important to note that introducing hypoallergenic novel foods does 
not change the number of food products that need to be avoided, unless the allergenic 
foods and ingredients are completely replaced with hypoallergenic alternatives, which is 
not a likely solution. Therefore, hypoallergenic novel foods may be more effective as 
allergy management strategy when they serve as replacement for allergenic foods that 
are easy to recognise and to avoid. It can be reasoned that because of this, the stress 
and anxiety related to the difficulties associated with allergen avoidance of widely used 
allergens is not reduced. Food allergic consumers are more positive about novel food 
innovations than food allergic consumers. This is the opposite of what had been 
expected at the start of the research. Food allergic consumer attitudes towards 
hypoallergenic novel foods were expected to be more positive than those of non-food 
allergic consumers because the former might experience benefits from hypoallergenic 
novel foods. A second reason for the lower consumer acceptance of novel foods may be 
that food allergic consumers have their daily lives and food allergy under control, which 
took them a lot of effort. When hypoallergenic novel foods are introduced, their situation 
changes and they need to adjust to those changes. This may make them more sceptical 
to any suggested food allergy management strategy that is not a cure. A third reason 
could be that the food allergic consumers are more cautious regarding the consumption 
of new foods, adopting a risk avoidance strategy, even if these risks are not perceived to 
be high. Hypoallergenic novel foods could offer food allergic consumers a wider food 
choice. This also becomes clear when looking at a food allergy quality of life 
questionnaire, which includes many aspects of quality of life that can be affected by food 
allergy (Flokstra-De Blok et al., in press). Theoretically, novel foods can only influence a 
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limited number of these items of quality of life. Therefore, the theoretical contribution of 
novel foods in improving quality of life is also limited. Quality of life of food allergic 
consumers is affected by many other factors than the foods they need to avoid and the 
foods that are available to them, such as their social environment. Novel foods are not 
likely to influence these social problems. This limitation may influence benefit perceptions 
of hypoallergenic novel foods, which may explain the low consumer acceptance of novel 
foods. Previous research shows that benefit perceptions are an important determinant of 
consumer acceptance. The willingness to purchase GM food is higher for low-allergen 
foods than for novel foods with no specified consumer benefit (Miles et al., 2006a). 
Health benefits are important, but they need to be specified to improve consumer 
acceptance. Apparently, some food allergic consumers perceive that the benefits from 
hypoallergenic novel foods outweigh the perceived risk and therefore are reluctant to 
accept novel foods. 
Some food allergic consumers may benefit more from the introduction of 
hypoallergenic novel foods as allergy management strategy than other food allergic 
consumers. It is not likely that all allergenic foods and ingredients in the food chain will 
be replaced with hypoallergenic counterparts. Therefore, consumers with an allergy to, 
for example, apple can now buy the non-allergenic apple Santana. The Santana apple 
(although strictly speaking not a novel food) does have benefits for consumers with an 
apple allergy. Some of these consumers can eat an apple again and these people are 
enthusiastic about this apple. This indicates that some hypoallergenic foods can have 
benefits for food allergic consumers. For food allergic consumers for whom food allergen 
avoidance is particularly difficult because they are allergic to an allergen that is used in 
many food products, like milk or wheat, replacement of this ingredient by a 
hypoallergenic counterpart is not a likely option. The relative contribution of 
hypoallergenic novel foods to a food allergy management strategy is therefore larger for 
consumers with an allergy to products that are easy avoidable. The relative contribution 
of novel foods to improving quality of life is therefore limited, but a positive effect can be 
expected, nevertheless. 
Another issue relating to the introduction of hypoallergenic novel foods into the 
food chain is acceptance by non-food allergic consumers. They do accept novel foods 
with specific benefits for food allergic consumers.  
When discussing the possibilities of applying hypoallergenic novel foods as 
allergy management strategy, it is important to realise that food allergic consumers prefer 
the development of a cure for food allergy over the development of hypoallergenic novel 
foods. This finding is in line with existing literature that states that prevention of disease 
should always be the first and foremost objective (Skripak and Sampson, 2008). When 
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making decisions about the allocation of future research funds, this should be taken into 
account. However, since at the time of writing the treatment options are limited to 
avoidance of the problematic foods and therefore facilitating food allergen avoidance 
through the introduction of hypoallergenic novel foods may be effective as part of an 
allergy management strategy. 
 
6.3 Practical implications 
The results presented in this thesis provide food allergic consumers with 
information regarding the introduction of hypoallergenic novel foods as part of food 
allergy management. The benefits associated with such a management strategy are 
expected to differ between food allergic consumers. Consumers who are allergic to 
allergens that are not present in many different products in the food chain are expected 
to benefit more from the introduction of hypoallergenic novel foods than consumers who 
are allergic to food ingredients that are used in many different products. In addition, it is 
important to realise that food allergies affect many aspects of food allergic consumers´ 
daily lives, such as the disbelief of the social environment and that hypoallergenic novel 
foods cannot improve all those. However, for some food allergic consumers 
hypoallergenic novel foods may become a valuable part of their food allergy 
management. 
 The results also show that although the novel foods that are developed were not 
intended to be used as part of an allergy management strategy, there were some 
examples that appeared to be hypoallergenic. This implies that the food industry could 
benefit additionally from the development of novel foods, if those are evaluated for 
potential hypoallergenicity as well. 
 The implications of this research for regulators are related to the potential 
benefits of hypoallergenic novel foods. Current novel food regulations are limited to the 
assessment of the safety of the novel foods. However, including the assessment of 
hypoallergenicity as benefit to the safety evaluation of novel foods would provide more 
certainty about the hypoallergenicity of novel foods to food allergic consumers, especially 
when the scientific community develops reliable (hypo)allergenicity assessment 
methods. 
 Since at the time of writing no hypoallergenic novel foods are available and their 
potential contribution to food allergy management is expected to be limited, it is not likely 
that health professionals can recommend food allergic consumers to include 
hypoallergenic novel foods in their diet. 
 
 101 
6.4 Research limitations and future research 
This research focussed on the application of novel foods as allergy management 
strategy. Since no hypoallergenic novel foods were available at the time this research 
was conducted, therefore it was not possible to perform an experiment in which food 
allergic consumers use hypoallergenic novel foods for a longer period of time, and 
quality of life is measured before and after this period of hypoallergenic novel food use. 
This means that the current research remains hypothetical. When in the future, 
hypoallergenic novel foods are available, it is recommended that an experiment is 
performed to test the hypothesis that hypoallergenic foods can influence quality of life. 
Further, including hypoallergenic foods that do not fall under the novel food regulation 
may provide useful insights into the possibilities of applying hypoallergenic foods as 
allergy management strategy. 
This thesis focussed on novel foods as part of a daily diet. Current research also 
focuses on the application of novel food proteins to allergen immunotherapy (Burks et 
al., 2008; Patriarca et al., 2009). It can be argued that when trying to achieve 
immunological tolerance to allergens the hypoallergenic novel foods have a more 
therapeutic function. While consumers do not perceive many benefits of hypoallergenic 
novel foods and their use in daily life, they may be more positive for these novel foods to 
be used therapeutically. Before hypoallergenic novel foods can be used as a therapeutic 
methods, it is advised that future research addresses consumer acceptance of novel 
foods as therapeutic method. Consumer acceptance of novel foods as therapy may be 
complicated by the fact that consumers will be exposed to doses of allergen, which may 
cause allergic reactions. However, it can be expected that consumer acceptance of 
novel foods is higher when they are applied as a therapy, since consumers expressed a 
preference for a cure for food allergy. 
Although some food allergic consumers indicate that the price of hypoallergenic 
novel foods should be comparable to traditional foods, others indicate that they are 
willing to pay an increased price for these hypoallergenic novel foods (Cornelisse-
Vermaat et al., 2008a). The extend to which food allergic consumers are willing to pay 
more for hypoallergenic foods with benefits to them could be subject of future research, 
once hypoallergenic foods with benefits for food allergic consumers have been identified. 
Novel foods may have more benefits for people who have recently been 
diagnosed and who need to learn how to deal with their food allergy, compared to food 
allergic consumers who have adjusted to living with a food allergy. Recently diagnosed 
food allergic consumers may benefit from a wider product choice when hypoallergenic 
 102
foods are available. Future research could focus on this aspect of hypoallergenic novel 
foods as allergy management strategy. 
 
6.5 Final conclusion 
 This thesis has provided insight into the possibilities and limitations of applying 
novel foods as part of an allergy management strategy. This research contributes to a 
better understanding of the impact of food allergy on daily life of food allergic consumers 
and shows that hypoallergenic novel foods may improve food allergen avoidance 
because food allergic consumers will have more foods to choose from. In addition, non-
food allergic consumers appear to be willing to accept novel foods in case those have 
benefits for food allergic consumers.  
The results of this thesis provide the food industry and regulators with important 
insights into the application of novel foods as allergy management strategy, enabling 
them to better respond to food allergic consumer needs regarding dealing with their food 
allergy. The food industry should pay attention to potential hypoallergenicity of newly 
developed foods, since the results in this thesis showed some examples of 
hypoallergenic foods that were not marketed as such. Regulators should include 
potential hypoallargenicity as part of a benefit assessment to the safety assessment of 
novel foods, to provide consumers and other stakeholders with as much certainty 
regarding remaining allergenicity as possible. 
 This thesis has extended existing research about novel foods and food allergy, 
and focussed on the introduction of hypoallergenic novel foods as part of an allergy 
management strategy. The results show that although hypoallergenic novel foods can 
facilitate allergen avoidance, their influence remains limited because many other factors, 
such as the recognition of their allergy by their social environment cause the food allergy 
problems. Nevertheless, considering that the food allergy management options are 
limited, the contribution that hypoallergenic novel foods, which can be replacement for 
allergenic foods may be valuable for consumers who are allergic to foods that are easy 
to recognise and avoid. 
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Summary 
 
Food allergy is an important health issue. It is defined as an inappropriate 
immunological reaction to normally harmless food components and affects 5-8% of 
children and 1-2% of adults. At the time of writing, the only reliable treatment of food 
allergy is strict avoidance of the problematic foods. Food allergy can have a profound 
impact on quality of life and economic functioning of food allergic consumers and their 
families, not only because of the immediate clinical effects related to an individual’s 
allergic condition, but also because of the alterations in daily life that have to be made to 
prevent the occurrence of symptoms. 
The introduction of novel foods is of interest to the management of food allergy 
for two reasons. On the one hand, the development and introduction of novel 
hypoallergenic foods represents a potential approach to reducing the negative health 
impacts of food allergy. On the other hand, the introduction of novel proteins into the 
food chain and the human diet may result in new cases of food allergy. Novel foods are 
defined as foods or food ingredients that have no history of safe use in the European 
Union (EU). The absence of a history of safe use can be the result of: (1) genetic 
modification of the food or production of the food using genetically modified organisms, 
(2) novel processing techniques, or (3) the food being new to the European Union. 
The research presented in this thesis explores whether novel foods can be used 
as part of an allergy management strategy. For novel foods to be used in food allergy 
management various factors must be considered. These include (1) the actual 
hypoallergenicity of novel foods, (2) consumer acceptance of novel foods in general and 
by food allergic consumers in particular, and (3) the potential impact of novel foods on 
the quality of life of food allergic consumers. 
In chapter 2 literature is reviewed to identify the issues associated with novel 
foods and food allergy. Food allergies can have a significant impact on the quality of life 
and economic functioning of people who suffer from them, as well as wider implications 
for society more generally. Direct costs of food allergy include medical costs, whereas 
indirect costs are linked to factors such as work and productivity. The latter have a much 
greater effect on individuals and families because these costs reflect the functioning and 
quality of life of the individual and his family. It is important to realise that the impact of 
food allergy on daily lives of food allergic consumers is not only a direct result from the 
disease and its symptoms, but also from the treatment: avoidance of the problematic 
foods. Restriction or complete elimination diets and emergency management of allergic 
reactions are at the time of writing the only reliable therapy to treat food allergy.  
 116
Another important issue is that there are both risks and benefits associated with 
the introduction of novel foods. Consumer acceptance of novel foods is contingent on 
technical risk estimates, and consumer perceptions of risks and benefits. An important 
finding from literature was the concept of risk conflict, which refers to the differences 
between the way that experts and non-experts evaluate risks. Technical risk 
assessments are often used by experts and regulators to determine acceptable safety 
levels, although consumer decision-making is, in part, based on broader, societally 
relevant factors of concern. People may tolerate some level of risk if they also perceive 
direct benefit. Novel foods with reduced of absent allergenicity may be perceived as 
beneficial by food allergic consumers and therefore acceptable. For non-food allergic 
consumers, the perceived risks may outweigh the benefits. Chapter 2 concludes that 
hypoallergenic novel foods, despite some uncertainty, have the potential to contribute to 
food allergy management, by aiding food allergen avoidance. However, it remained 
unclear what the allergy risks of novel foods are. 
Because of the different perceptions concerning risks among experts and 
consumers, chapter 3 looked at whether novel foods can be used as allergy 
management strategy from both a stakeholder and food allergic consumer perspective. 
Most stakeholders believed that novel foods can, in theory, contribute to a solution for 
the food allergy problems they described because the novel foods can be 
hypoallergenic, and therefore they may represent a safe alternative for food allergic 
consumers. The stakeholders also mentioned some potential problems when novel 
foods are introduced, such as consumers who develop allergies to the novel proteins in 
novel foods. They also stressed that novel foods can only be effective as food allergy 
management strategy if consumers are willing to buy them. Food allergic consumers 
would be in favour of hypoallergenic novel foods being developed and commercialised. 
However, they did express doubts regarding the reduced allergenicity of such novel 
foods. Consumers perceived that novel foods could only be used as allergy management 
strategy when all allergenic food ingredients are replaced across all food chains 
completely. Both stakeholders and food allergic consumers expressed some enthusiasm 
for the introduction of truly hypoallergenic novel foods. Whilst the results suggest that 
hypoallergenic novel foods may be acceptable to food allergic consumers, consumers 
expressed the view that a ‘cure’ for food allergy is preferred over substituting existing 
foods with hypoallergenic alternatives. 
In chapter 4 consumer attitudes towards novel foods are identified and the impact 
of information about food allergy and novel foods on non-food allergic consumer 
acceptance is assessed. The results show that hypoallergenic novel food acceptance as 
allergy management is more acceptable to consumers who perceive high benefits and 
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low or medium risks. Many food allergic consumers did not perceive the benefits of 
hypoallergenic novel foods to be high and were less accepting of hypoallergenic novel 
foods as allergy management strategy. Both food allergic consumer and non-food 
allergic consumer acceptance of novel foods was higher for natural novel foods 
compared to genetically modified novel foods. It is concluded that the application of 
novel foods as an allergy management strategy is complicated because many of the 
consumers who are supposed to experience the benefits of these novel foods are less 
likely to use these novel foods. 
Chapter 5 reviews the existing legislation associated with the introduction of novel 
foods and assesses the efficacy of such legislation with respect to allergy risks and 
benefits. Various regulations are in place to protect consumer health. These regulations 
require novel food safety to be assessed before they can enter the market. However, the 
current regulatory frameworks do not specify how these assessments should be 
performed. This may relate to the fact that the safety assessment methods available and 
best suited depend on the type of novel food under assessment. None of the safety 
assessment include benefits assessment. However, when a hypoallergenic novel food 
with benefits for food allergic consumers is being evaluated, it can be argued that 
information about the potential benefits should be formally included in management 
decisions and therefore the assessment of benefits would be helpful. 
Overall, the results in this thesis suggest that the potential contribution of novel 
foods as part of an allergy management strategy is limited. The first reason for this 
conclusion is that no hypoallergenic novel foods could be identified. However, it is 
possible that some hypoallergenic new foods exist that fall outside the definition of novel 
foods as used in this thesis. The second reason concerns the limited influence that can 
be expected of novel foods. The most important factor affecting quality of life of food 
allergic consumers is the avoidance of food allergens. Application of hypoallergenic 
foods through the food chain is necessary to reduce the number of food products that 
food allergic consumers need to avoid. However, replacement of all allergenic foods and 
ingredients through the food chain is not likely. This implies that only novel foods that are 
not used as ingredient in many other foods can be used to replace allergenic foods. In 
general, the foods that are not used as an ingredient in many other products are easier 
to avoid. A third reason for the limited potential of hypoallergenic novel foods to be used 
as allergy management strategy concerns the uncertainty regarding the results of the 
allergenicity assessment, which always are a conclusion as to the likelihood of a food 
being an allergen. For a food to be applied as part of an allergy management strategy as 
much certainty as possible is required, especially for food allergic consumers who will 
experience severe life threatening symptoms when exposed to food allergens. However, 
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considering the limited number of allergy management strategies, it can be argued that 
any contribution, including hypoallergenic novel foods, to food allergy management 
would be welcomed.  
Overall, this research contributes to a better understanding of the impact of food 
allergy on daily lives of food allergic consumers and shows that hypoallergenic novel 
foods may improve certain aspects of daily lives of some food allergic consumers, 
through improved allergen avoidance. The results of this thesis provide the food industry 
and regulators with important insights into the application of novel foods as allergy 
management strategy, enabling them to better respond to food allergic consumer needs 
regarding dealing with their food allergy. 
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Samenvatting (Dutch summary) 
 
Voedselallergie is een belangrijk gezondheidsprobleem. Voedselallergie is 
gedefinieerd als een misplaatste immunologische reactie op voedsel dat bij niet 
allergische consumenten geen schadelijke reactie veroorzaakt. Ongeveer vijf tot acht 
procent van de kinderen en een tot twee procent van de volwassenen hebben last van 
een voedselallergie. Op het moment van dit schrijven is de enige behandelmogelijkheid 
voor mensen met een voedselallergie het strikt vermijden van de problematische 
voedingsmiddelen. Voedselallergie kan een grote invloed hebben op de kwaliteit van 
leven van consumenten met een voedselallergie en hun gezin. Daarnaast heeft een 
voedselallergie vaak ook financiële gevolgen. Niet alleen vanwege de directe klinische 
gevolgen van de allergische aandoening, maar ook door de aanpassingen die in het 
dagelijkse leven gedaan moeten worden om allergische symptomen te voorkomen. 
De introductie van ‘novel foods’ is interessant wat betreft het beheersen van 
voedselallergieën om twee redenen. Enerzijds biedt de ontwikkeling en introductie van 
hypoallergene ‘novel foods’ een potentiële benadering om de negatieve gevolgen van 
voedselallergie te beperken. Anderzijds kan de introductie van nieuwe eiwitten in de 
voedselketen en het dieet van mensen resulteren in nieuwe voedselallergieën. ‘Novel 
foods’ worden gedefinieerd als voedingsmiddelen, of voedingsingrediënten die geen 
verleden hebben van veilig gebruik in de Europese Unie (EU). The ontbreken van dat 
verleden kan het gevolg zijn van: (1) genetische modificatie van het voedsel, of een 
productiewijze waarbij genetisch gemodificeerde organismen worden gebruikt, (2) 
toepassing van nieuwe bewerkingsmethoden, of (3) het voedsel is nieuw in de EU. 
Het onderzoek dat in dit proefschrift wordt gepresenteerd verkent of ‘novel foods’ 
gebruikt kunnen worden als onderdeel van een allergiemanagementstrategie. Voordat 
‘novel foods’ gebruikt kunnen worden als voedselallergie management moet rekening 
gehouden worden met een aantal factoren, zoals (1) de hypoallergeniciteit van de ‘novel 
foods’, (2) consumenten acceptatie van ‘novel foods’ in het algemeen en door 
consumenten met een voedselallergie in het bijzonder en (3) de potentiële invloed van 
‘novel foods’ op de kwaliteit van leven van voedselallergische consumenten. 
In hoofdstuk 2 is literatuur bestudeerd om de kwesties gerelateerd aan ‘novel 
foods’ en voedselallergie te identificeren. Voedselallergieën kunnen een aanzienlijke 
invloed hebben op de kwaliteit van leven en de financiële situatie van mensen met een 
voedselallergie. Daarnaast kunnen ze ook gevolgen hebben voor de hele samenleving. 
Directe kosten van voedselallergie zijn medische kosten. De indirecte kosten zijn 
gerelateerd aan werk en productiviteit. Indirecte kosten hebben een groter effect op 
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individuele consumenten en de mensen in hun omgeving. Het is belangrijk te beseffen 
dat de invloed van voedselallergie op het dagelijkse leven van consumenten met een 
voedselallergie geen direct gevolg is van de ziekte en de symptomen, maar vooral een 
gevolg is van de behandelwijze: het vermijden van problematische voedingsmiddelen. 
Het beperken of compleet elimineren van de inname van specifieke voedingsmiddelen 
en het behandelen van allergische reacties in noodgevallen zijn op het moment van dit 
schrijven de enige betrouwbare behandelmethode voor voedselallergie. Een belangrijke 
kwestie omtrent de introductie van ‘novel foods’ is dat er zowel risico’s als voordelen aan 
verbonden zijn. Consumentenacceptatie van ‘novel foods’ is afhankelijk van technische 
risicoschattingen en het beeld dat consumenten hebben van de risico’s en voordelen. 
Een belangrijke resultaat van de literatuurstudie is het concept van ‘risk conflict’ dat 
refereert aan de verschillende manieren waarop experts en leken risico’s beoordelen. 
Technische risicobeoordelingen worden vaak gebruikt door experts en wetgevers om 
acceptabele veiligheidsniveaus te bepalen, terwijl consumentenbeslissingen deels 
gebaseerd zijn op bredere sociale factoren. Mensen accepteren wellicht een bepaald 
risico indien zij ook direct voordeel hebben. Voedselallergische consumenten kunnen het 
beeld hebben dat ‘novel foods’ met verminderde of geen allergeniciteit voordelen hebben 
voor hen en daardoor deze voedingsmiddelen accepteren. Voor consumenten zonder 
voedselallergie kan het beeld van de risico’s van deze voedingsmiddelen zwaarder 
wegen dan hun beeld van de voordelen. Hoofdstuk 2 concludeert dat hypoallergene 
voedingsmiddelen mogelijk een bijdrage kunnen leveren aan voedselallergie 
management, ondanks enige onzekerheid, doordat het vermijden van allergenen 
vergemakkelijkt wordt. Het blijft onduidelijk wat de risico’s van ‘novel foods’ zijn. 
Vanwege de verschillende beeldvormingen van de risico’s van ‘novel foods’ bij 
experts en consumenten bekeek hoofdstuk 3 of ‘novel foods’ gebruikt kunnen worden 
om voedselallergieën te beheersen vanuit het standpunt van experts en 
voedselallergische consumenten. De meeste experts geloofden dat ‘novel foods’ in 
theorie een bijdrage kunnen leveren aan een oplossing voor de 
voedselallergieproblematiek zoals zij die beschreven, doordat ‘novel foods’ mogelijk 
hypoallergeen zijn en daardoor een veilig alternatief kunnen bieden aan consumenten 
met een voedselallergie. De experts beschreven ook een aantal mogelijke problemen die 
kunnen ontstaan bij de introductie van ‘novel foods’ zoals het ontwikkelen van een 
allergie voor eiwitten in deze ‘novel foods’. Ze benadrukten ook dat ‘novel foods’ alleen 
effectief kunnen zijn als voedselallergiemanagement indien consumenten bereid zijn de 
‘novel foods’ te kopen. Voedselallergische consumenten waren voorstander van de 
ontwikkeling en verkoop van hypoallergene voedingsmiddelen. Zij twijfelden wel of ‘novel 
foods’ daadwerkelijk hypoallergeen zouden kunnen zijn. Ze gaven aan dat ‘novel foods’ 
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alleen gebruikt kunnen worden als allergiemanagement als alle allergene varianten van 
dat product vervangen zouden worden in de gehele voedselketen. Zowel de experts als 
de consumenten waren in enige mate enthousiast over de introductie van hypoallergene 
voedingsmiddelen. Hoewel de resultaten laten zien dat hypoallergene ‘novel foods’ 
geaccepteerd zouden worden door voedselallergische consumenten geven deze 
consumenten de voorkeur aan het genezen van hun voedselallergie. 
In hoofdstuk 4 werden consumentenattitudes ten aanzien van ‘novel foods’ 
geïdentificeerd. Daarnaast werd de invloed van informatie over het hebben van een 
voedselallergie en ‘novel foods’ op acceptatie door consumenten zonder voedselallergie 
bekeken. De resultaten laten zien dat acceptatie van hypoallergene ‘novel foods’ groter 
is bij consumenten die veel voordelen zien en weinig of gemiddelde risico’s. Veel 
voedselallergische consumenten zagen geen of weinig voordelen van ‘novel foods’ en 
hun acceptatie van hypoallergene ‘novel foods’ was lager. Zowel consumenten met een 
voedselallergie als ook consumenten zonder voedselallergie vonden natuurlijke ‘novel 
foods’ meer acceptabel dan genetisch gemodificeerde ‘novel foods’. De conclusie is dat 
de toepassing van ‘novel foods’ als allergiemanagement strategie gecompliceerd is 
vanwege het feit dat juist die consumenten die verwacht werden voordelen te ervaren 
van ‘novel foods’, het minst geneigd zijn de producten te gebruiken. 
Hoofdstuk 5 bekeek de huidige ‘novel food’ regelgeving en beoordeelt de 
doeltreffendheid van die regelgeving met betrekking tot allergierisico’s en -voordelen. 
Verscheidene wet- en regelgeving bestaat met als doel de gezondheid van consumenten 
te beschermen. Deze stellen dat de veiligheid van ‘novel foods’ beoordeeld moet worden 
voordat ze op markt toegelaten kunnen worden. De huidige wet- en regelgeving stelt niet 
hoe die veiligheid bepaald moet worden. Dit kan te maken hebben met het feit dat de 
beschikbare en meest geschikte methodes om de veiligheid te beoordelen afhankelijk 
zijn van het type ‘novel food’ dat beoordeeld moet worden. Geen van de 
veiligheidsbeoordelingen omvatten ook een beoordeling van de mogelijke voordelen. 
Indien een hypoallergeen ‘novel food’ met voordelen voor consumenten met een 
voedselallergie beoordeeld wordt, is het niet ondenkbaar dat informatie over de 
potentiële voordelen meegenomen moet worden in management besluiten. Hierbij zou 
een formele beoordeling van de voordelen behulpzaam zijn. 
De resultaten in dit proefschrift suggereren dat de potentiële bijdrage van ‘novel 
foods’ aan voedselallergiemanagement beperkt is. De eerste reden voor deze conclusie 
is dat geen hypoallergene ‘novel foods’ lijken te bestaan. Desalniettemin is het mogelijk 
dat hypoallergene nieuwe voedingsmiddelen bestaan die niet onder de definitie van 
‘novel foods’ vallen, zoals die in dit proefschrift gehanteerd is. De tweede reden betreft 
de beperkte invloed van ‘novel foods’ op de voedselallergieproblematiek. Kwaliteit van 
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leven wordt het meest beïnvloed door de hoeveelheid voedingsmiddelen die vermeden 
dient te worden. Het introduceren van hypoallergene voedingsmiddelen in de 
voedselketen, waarbij de allergene producten vervangen worden is noodzakelijk om het 
aantal voedingsmiddelen dat voedselallergische consumenten dienen te vermijden te 
verminderen. Het is echter niet waarschijnlijk dat alle allergene producten in de 
voedselketen vervangen kunnen worden door hypoallergene varianten. Dit betekent dat 
slechts ‘novel foods’ die niet als ingrediënt in veel andere producten gebruikt worden 
gebruikt kunnen worden als vervanging. Een derde reden voor de beperkte 
mogelijkheden hypoallergene ‘novel foods’ als allergiemanagement strategie te 
gebruiken betreft de onzekerheid over de resultaten van de allergeniciteitsbeoordeling. 
Deze geven slechts een indicatie van de waarschijnlijkheid dat een eiwit een allergeen 
is. Voordat een voedingsmiddel gebruikt kan worden als onderdeel van een 
voedselallergiemanagementstrategie moet zoveel mogelijk zekerheid bestaat over de 
resterende allergeniciteit. Dit geldt in het bijzonder voor voedselallergische consumenten 
die levensbedreigende symptomen krijgen als zij blootgesteld worden aan allergenen. In 
aanmerking genomen dat er slechts weinig voedselallergiemanagement opties zijn is er 
iets voor te zeggen dat iedere bijdrage aan een managementstrategie, zoals de 
introductie van hypoallergene ‘novel foods’ welkom is.  
Dit onderzoek draagt bij aan het inzicht in de invloed van voedselallergieën op 
het dagelijkse leven van consumenten met een voedselallergie en laat zien dat 
hypoallergene ‘novel foods’ het dagelijkse leven van sommige voedselallergische 
consumenten kan verbeteren, door het gemakkelijker maken allergenen te vermijden. De 
resultaten van dit onderzoek bieden de voedselindustrie en wet- en regelgevers 
belangrijke inzichten in de mogelijkheden ‘novel foods’ toe te passen als 
allergiemanagementstrategie, waardoor zij in staat zijn beter op de behoeften van 
voedselallergische consumenten in te spelen. 
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